CN1056083C - 治疗及修复软骨缺损或损伤的方法及组合物 - Google Patents

治疗及修复软骨缺损或损伤的方法及组合物 Download PDF

Info

Publication number
CN1056083C
CN1056083C CN92101431A CN92101431A CN1056083C CN 1056083 C CN1056083 C CN 1056083C CN 92101431 A CN92101431 A CN 92101431A CN 92101431 A CN92101431 A CN 92101431A CN 1056083 C CN1056083 C CN 1056083C
Authority
CN
China
Prior art keywords
substrate
tgf
cartilage
defect
repair
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN92101431A
Other languages
English (en)
Other versions
CN1064813A (zh
Inventor
E·B·亨齐克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1064813A publication Critical patent/CN1064813A/zh
Application granted granted Critical
Publication of CN1056083C publication Critical patent/CN1056083C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028Polypeptides; Proteins; Degradation products thereof
    • A61L26/0047Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/185Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51Lyases (4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001Use of materials characterised by their function or physical properties
    • A61L24/0015Medicaments; Biocides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10Polypeptides; Proteins
    • A61L24/106Fibrin; Fibrinogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10Polypeptides; Proteins
    • A61L24/108Specific proteins or polypeptides not covered by groups A61L24/102 - A61L24/106
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/22Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2/30756Cartilage endoprostheses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412Tissue-regenerating or healing or proliferative agents
    • A61L2300/414Growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/426Immunomodulating agents, i.e. cytokines, interleukins, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45Mixtures of two or more drugs, e.g. synergistic mixtures
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/626Liposomes, micelles, vesicles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/06Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/84Bones; tendons; teeth; cartilage

Abstract

本发明提供了治疗和修复人和其他动物软骨缺损或损伤的方法及组合物。首先用酶处理软骨的缺损或损伤部位,使蛋白多糖从缺损区域去除。为了诱导软骨形成,用带孔的可生物降解基质填充或敷裹缺损部位,其孔的大小足以使修复细胞聚居于基质中。填充缺损的基质含有增殖剂,其浓度足以刺激修复细胞增殖,以及在合适传送系统中的转化因子,该系统释放出足使基质和缺损区域中的修复细胞转化成为产生软骨的软骨细胞浓度的转化因子。基质还可以含有趋化剂以吸引修复细胞。整个治疗可以在单独一个关节镜下或开放式外科手术过程中进行。

Description

治疗及修复软骨缺损或损伤的方法及组合物
本发明涉及治疗和修复软骨缺损或损伤。特别是本发明涉及治疗软骨缺损或损伤(本文中可以互换使用)的方法和含有可生物降解基质的组合物,该基质含有一种或多种增殖剂以促进修复细胞增殖形成新的稳定的软骨组织。本发明的组合物及方法特别适用于治疗骨关节炎和产生软骨损伤的其他疾病与创伤。
关节是联接骨骼中骨头的普通方式之一。正常的关节联接的骨头的末端是被关节软骨组织覆盖住的,这样就使得骨骼在运动时不会相互摩擦〔L.Weiss,ed.,细胞与组织生物学(Munchen:Urban and Schwarzenburg,1988)第247页〕。
关节的软骨是以特别结构的组织为特征的。它由特定的细胞(软骨细胞)组成,这些细胞包埋在胞间物质(在文献中通常指“软骨基质”)中,该物质富含蛋白多糖,主要为II型的胶原原纤维,其他蛋白质和水〔Buckwalter等人,“关节的软骨:损伤与修复”,Injury and Repair of the MusculoskeletalSoft Tissues(Park Ridge,I11:AmericanAcademy of Orthopaedic Surgeons Symposium,1987),第465页〕。软骨组织既不受神经支配,又不被血管或淋巴系统穿过。但是在成年人的成熟关节中,软骨下的骨组织在骨组织与软骨之间形成一个狭窄的、连续的板,它是受神经支配的并且形成了血管。在此骨板下,骨组织形成,其中含有骨髓的小梁。在未成熟的关节中,关节软骨只是作为主要骨小梁的衬里。关节中的部分半月板组织也由软骨构成,其组成与关节的软骨相似〔Beaupre,A.等人,Clin.Orthop.Rel.Res.第72-76页,(1986)〕。
在软骨组织中有两种类型的缺损或损伤是公认的,即完全增厚缺损和表面缺损。这两种缺损的区别不仅在于软骨物理损伤的程度,也在于每种损伤所能引起的修复应答的性能。
完全增厚损伤蔓延至软骨下的骨头上,并且由于骨板含有感觉神经末梢能够引起剧痛。这种缺损一般由严重创伤所致或者在退化性关节疾病(如骨关节炎)的晚期产生。完全增厚缺损有时会导致出血并且诱导软骨下骨头的修复反应〔Buckwalter等人,“ArticularCartilage:Composition,Structure,Responseto Injury and Methods of FacilitatingRepair”Articular Cartilage and KneeJoint Function:Basic Science andArthroscopy(New York:Raven Press,1990)第19-56页〕。所形成的修复组织是血管化纤维型的软骨,其生物力学性质不足,并且不能长期坚持〔Buckwalter等人,(1990),上文〕。
关节软骨组织的表面缺损限于软骨组织本身。这种缺损很讨厌是众所周知的,因为它们无法治愈并且不具有修复反应的倾向。
这些缺损可以表现为在软骨表面中的裂隙、削起或裂口,或者它们可以在受侵袭的组织中具有“螃蟹肉”外观。它们不含有象在完全增厚缺损中所见的出血血管(血斑)。表面缺损的起因可能不知道,但通常它们是导致软骨组织摩损机械紊乱的结果,机械紊乱可以由关节创伤引起,例如撕裂的半月板组织移位至关节中、半月板切除术、因韧带撕裂所致关节松弛、关节排列不齐或者骨折,或者因遗传病引起。表面缺损的特征还在于早期退化性关节疾病,例如骨关节炎。由于软骨组织不受神经支配〔Ham′S Histology(第9版)(Philadelphia:J.B.Lippincott Co.1987),第266-272页〕或者是非血管化的,因此表面缺损是无痛苦的。但是,尽管无痛苦,表面缺损却无法治愈,并且经常转为完全增厚缺损。
一般认为,由于关节软骨缺少脉管系统,损伤的软骨组织不能得到足够的或适当的刺激以引起修复应答〔Webber等人,“Intrinsic Repair Capabilities of RabbitMeniscal Fibrocartilage:A Cell CultureModel”,(30th Ann.Orthop.Res.Soc.,Atlanta,Feb.1984);Webber等人,J.Orthop.Res.,3,第36-42页(1985)〕。可以推测,软骨组织中的软骨细胞正常情况下不与足够量的修复刺激剂例如生长因子和纤维蛋白凝块接触,这些刺激剂典型地存在于损伤的血管化组织中。
一种用于将损伤的软骨组织与修复刺激剂接触的方法包括穿过软骨钻入或刮至软骨下的骨头中引起出血〔Buckwalter等人,1990.上文〕。不幸的是,该组织对这为外科手术损伤的修复应答通常与完全增厚缺损引起出血中所观察到的自然产生的应答相类似,即形成纤维型软骨,其生物力学性质不足并且不能长期坚持〔Buckwalter等人,1990,上文〕。
已经分离出多种生长因子,并且目前已可供用于研究和生物医学应用〔见例如Rizzino.A.,Dev.Biol.130,第411-22(1988)〕。已有报导,这些生长因子中的一些例如转化生长因子β(TGF-β)在体外在胚胎大鼠间质细胞中能促进特定的软骨分子形成,例如II型胶原和特定的软骨蛋白多糖〔例如Seyedin等人,Proc.Natl.Acad.Sci.USA,82,第2267-71页(1985);Seyedin等人,J.Biol.Chem.,261,第5693-95页(1986);Seyedin等人,J.Biol.Chem.262,第1946-1949页(1987)〕。
已经有上百万患者被诊断患有骨关节炎,即在他们的关节软骨中患有退化性缺损或损伤。然而,尽管有各种方法声称可以在损伤的软骨中引起修复应答,但是这些方法中没有任何一种被接受实际应用〔Buckwalter等人(1990),上文;Knutson等人,J.Bone and Joint Surg.,68-B,第795页(1986);Knutson等人,J.Bone and JointSurg.,67-B,第47页(1985);Knutson等人,Clin.Orthop.,191,第202页(1984);MarquetClin.Orthop.,146,第102页(1980)〕。并且这些治疗方法一般只是暂时缓解。全身使用“软骨保护剂”也打算用于阻止骨关节炎发展并用于引起疼痛缓解。但是这种保护剂未显示出促进软骨组织中损伤或缺损的修复。
到目前为止,患有骨关节炎患者的治疗主要是通过使用止痛药和消炎剂直接缓解症状。在不使用能引起关节软骨中表面缺损修复的治疗方法下,软骨经常摩损到软骨下的骨板。在该疾病即严重骨关节炎的这一阶段,持续的疼痛和显著的功能衰退经常导致整个关节被切除,并且用一个金属和/或塑料的人工关节代替。目前每年有50万人实施膝和髋关节切除与人工关节替换手术。〔见例如Graves,E.J.,“1988 Summary;National HospitalDischarge Survey”,Advanced Data FromVital and Health Statistics,185,第1-12页,(1990年6月19日)〕。
因此需要可靠的治疗软骨缺损的方法,该方法能够引起修复并使稳定的软骨再生,并且防止表面软骨缺损或损伤发展成为严重的骨关节炎。
本发明通过提供有效的治疗方法和组合物以引起人和其他动物软骨损伤的修复而解决了上面所提到的问题。使用本发明的方法和组合物还可以防止创伤损伤的发展和骨关节炎的早期形成,否则将导致持续疼痛并丧失有效关节功能的严重的骨关节炎,它将导致该关节可能被切除和替换。
总的来讲,本发明修复软骨缺损的方法包括用本发明组合物填充或者覆盖软骨的缺损处,该组合物含有(1)可生物降解的基质或形成基质的材料,(2)促进基质和缺损区域中修复细胞的增殖的,以及在某些具体情况下(3)以吸引修复细胞到基质和缺损区域中去的趋化剂,和(4)存在于合适传送系统中的转化因子,该系统将在合适的时间释放该转化因子以促进基质或缺损区域中的修复细胞分化(即转化)成为产生新的稳定的软骨组织的软骨细胞。或者,可以在适当的时候将转化因子单独加至缺损部位。
在进行单独的关节镜检查和外科术过程中可以使用本发明的方法治疗软骨缺损。根据本发明的某些方法,在确定缺损后,通过下列步骤治疗缺损:(1)用一种酶填充缺损区域,这种酶能使存在于缺损表面的蛋白多糖降解,(2)除去该酶,(3)用一种组合物敷裹缺损,该组合物含有基质、增殖剂和存在于一个合适传送系统中的转化因子。
为了更充分地理解本发明,下面将进行详细的描述。在说明书中使用下列术语。
关节镜检查——用在本文中是指使用关节镜对关节进行检查或进行外科术。
软骨——用在本文中是指一种类型的联接组织,它含有被胞间物质(通常称作“软骨基质”)包裹的软骨细胞,该基质含有胶原原纤维(主要是II型胶原与其他次要类型的胶原,如IX和XI型)、各种蛋白多糖(例如软骨素硫酸蛋白多糖、角质素硫酸蛋白多糖和皮肤素硫酸蛋白多糖)、其他蛋白质和水。本文所用的软骨包括关节和半月板软骨。关节软骨覆盖于关节中骨骼部分的表面,使关节运动时骨与骨之间不直接接触,因而防止摩损和损伤骨表面。多数正常健康的关节软骨又被描述为“玻璃样的”即具有磨砂玻璃外观这样的特征。通常发现关节中的半月板软骨经受震动和运动。这些部位的半月板软骨包括颞下颌关节、胸锁骨关节、肩峰锁骨关节、腕关节和膝关节〔Gray′s Anatomy(New York:Bounty Books,1977)〕。
细胞粘附促进因子——在本文中是指能够介导细胞粘附于胞外基质的任何化合物或组合物,包括fibronectin和其他与四肽一样小的肽,其中含有三肽Arg-Gly-Asp〔Ruoslathi等人,Cell,44,第517-518(1986)〕。
趋化剂——在本文中用以指在体外趋化性分析中能按标准吸引细胞的任何化合物或组合物,包括肽、蛋白质、糖蛋白和葡糖氨聚糖链〔例如Wahl等人,Proc.Natl.Acad.Sci.USA,84,第5788-92(1987);Postlewaite等人,J.Exp.Med.,165,第251-56页(1987);Moore等人,Int.J.Tiss.Reac.,XI,第301-07(1989)〕。
软骨细胞——在本文中用来指能够产生软骨组织成分例如II型软骨原纤维和纤维以及蛋白多糖的细胞。
成纤维细胞生长因子(FGF)——从天然、合成或重组来源获得的FGF多肽族中的任何成员或其衍生物〔Gimenez-Gall-ego等人,Biochem.Biophys.Res.Commun.,135,第541-548(1986);Thomas等人,TrendsBiochem.Sci.,11,第81-84页(1986)〕,它们能够刺激各种细胞,包括主要的成纤维细胞、软骨细胞、血管和角膜内皮细胞、成骨细胞、成肌细胞、平滑肌和神经胶质细胞〔Thomas等人,1986,上文〕的DNA合成和细胞体外分裂〔对于分析可参见例如Gimenez-Gallego等人,1986,上文;Canalis等人,J.Clin.Invest.,81,第1572-1577(1988)〕。FGF根据其等电点(PI)可以分成酸性FGF(aFGF)和碱性FGF(bFGF)两类。
基质——本文中是指多孔复合的、固体或半固体可生物降解的物质,它具有足够大的孔或空间使细胞可以聚居于该基质中。术语“基质”包括形成基质的材料,即能够在软骨的缺损部位中形成基质的材料。形成基质的材料可以需要添加聚合剂以形成基质,例如向含有纤维蛋白原的溶液中加入凝血酶,以形成纤维蛋白基质。
增殖(促有丝分裂)剂——在本文中是指能够在体外刺激细胞增殖的任何化合物或组合物,包括肽、蛋白质和糖蛋白。在体外分析中,测定肽、多肽和其他化合物的增殖(促有丝分裂)活性是本领域众所周知的〔见例如Canalis等人,J.Clin.Invest.第1572-77(1988);Gimenez-Gallego等人,Biochem.Biophys.Res.Commun.,135,第541-548页(1986),Rizzino,“Soft Agar GrowthAssays for Transforming Growth Factorsand Mitogenic Peptides”,Methods Enzymol.,146A(New York:Academic Press,1987),第341-52页;Dickson等人,“Assays of Mitogen-Induced Effects on Cellular Incorpora-tion of Precursors for Scavengers,deNovo,and Net DNA Synthesis”,MethodsEnzymol.146A(New York:Academic Press,1987),第329-40页〕。一种测定化合物或组合物增殖(促有丝分裂)活性的标准方法是在体外测定其在软琼脂中诱导非转化细胞非固定依赖性生长的能力〔例如Rizzino,1987,上文〕。其他促有丝分裂活性测定体系也是已知的〔例如Gimenez-Gallego等人,1986,上文;Canalis等人,1988,上文;Dickson等人,1987,上文〕。
修复细胞——本文中用于指当经受合适的刺激时,能分化并转化成为软骨细胞的细胞。修复细胞包括间质细胞、成纤维细胞、类成纤维细胞的细胞、巨噬细胞和消分化软骨细胞。
转化因子——是指能诱导修复细胞分化成为软骨细胞的任何肽、多肽、蛋白质或任何其他的化合物或组合物。化合物或组合物诱导或刺激细胞产生软骨特异的蛋白多糖和II型胶原的能力可以通过现有技术已知的体外分析法测定〔Seyedin等人,Proc.Natl.Acad.Sci.USA,82,第2267-71页(1985);Seyedin等人,Path.Immunol.Res.,7,第38-42页(1987)〕。
转化生长因子β(TGF-β)--从天然合成或重组来源获得的TGF-β多肽族中任何一个成员或其衍生物〔Derynck,R.等人,Nature,316,第701-705页(1985);Roberts等人,“The trasforming growth factor-β′s”,Peptide growth factors and theirreceptors I(Berlin:Springer.Verlag,1990),第419页〕,它在软琼脂分析中具有刺激正常鼠肾(NRK)细胞生长并形成克隆的特征性的TGF-β能力〔Roberts等人,1984,上文〕,并且正如它能够在体外通过细胞诱导或刺激产生软骨的特异的蛋白多糖和II型胶原所证实的,它能够诱导修复细胞转化成为软骨细胞〔Seyedin等人,1985,上文〕。
本发明涉及治疗软骨缺损或损伤的组合物及方法。本发明的组合物含有可生物降解的基质,该基质具有足够大的孔,使修复细胞能聚居于基质中。该基质还含有增殖剂以刺激基质中修复细胞的增殖。特别是,该增殖剂还具有趋化剂的作用,以吸引修复细胞至基质中。或者,该基质除含有增殖剂外,还含有趋化剂。在本发明优选的具体例子中,该基质还含有合适浓度的转化因子,该转化因子被包含在或结合在传送系统中,该传送系统在适当的时候有效地释放转化因子,将基质中增殖的修复细胞转化为软骨细胞,由软骨细胞产生稳定的软骨组织。该基质还可以含有细胞粘附促进因子。
适用于本发明方法和组合物中以填充或者敷裹软骨缺损的基质材料包括纤维蛋白原(被凝血酶激活,在缺损或损伤处形成纤维蛋白)、胶原、琼脂糖、明胶和任何其他的可生物降解材料,它们能形成具有足够大孔的基质,使得修复细胞能够在基质中聚居并增殖,它们在修复过程中可以被降解并且被软骨替换。
适用于本发明组合物和方法中的此基质可以预制或新鲜配制,例如通过聚合化合物和组合物如纤维蛋白原形成纤维蛋白基质。可以预制的基质包括胶原(如胶原海绵和胶原羊毛状物)、化学修饰的胶原、明胶珠或明胶海绵、形成凝胶的物质如琼脂糖、任何其他形成凝胶的物质或复合物质,它由可生物降解的基质材料组成,该材料将填充于缺损处使修复细胞聚居于基质中,或者上述物质的混合物。
在本发明优选的具体例子中,使用形成基质的材料、优选纤维蛋白原溶液形成基质,在使用前向其中加入凝血酶使其立刻开始聚合。可以使用的纤维蛋白原的浓度为0.5-5mg/ml水缓冲液。优选使用1mg/ml含水缓冲液的纤维蛋白原溶液。该纤维蛋白原溶液在缺损区域聚合,产生具有足够大尺寸(例如约50-200μm)孔的基质,使修复细胞自由聚居于基质中并增殖,以填充基质所占领的缺损体积。优选的是,在使用前不久向纤维蛋白原溶液中加入足量的凝血酶,以在完成聚合前使外科医生有足够的时间将此材料存放于缺损区域。通常凝血酶的浓度应该是使聚合在很少时间至几分钟(2-4分钟)之间完成,因为软骨长时间暴露于空气中将会引起损伤〔Mitchell等人,J.Bone Joint Surg.,71A,第89-95页(1989)〕。不能使用过量的凝血酶,因为凝血酶能够使生长因子分子断裂并使它们灭活。加入到纤维蛋白原溶液中的凝血酶溶液可以制备成每ml含水缓冲液10-500单位,优选100单位。在本发明优选的具体例子中,在填充缺损前,将20μl凝血酶(100μ/ml)与每ml纤维蛋白原溶液(1mg/ml)混合200秒。如果加入凝血酶的浓度较低,则聚合发生得较慢。很显然,所给出的使纤维蛋白在2-4分钟之内聚合所需的凝血酶溶液的量只是大约的,因为这个量取决于环境温度,凝血酶溶液的温度和纤维蛋白原溶液的温度等。通过观测凝血酶诱导的纤维蛋白原溶液外部样品的聚合,可以很容易地监测填充至缺损处的凝血酶活化的基质溶液的聚合。在本发明组合物和方法中,优选的纤维蛋白基质是从自体纤维蛋白原分子形成的,即纤维蛋白原分子是从与被治疗的物种相同的哺乳动物种的血液中获得的。从该物种获得的非免疫原纤维蛋白原也可以使用。
当使用胶原作基质材料时,可以制成足够粘度的溶液,例如使用Collagen-Vliess(“羊毛状的”)或明胶-血液混合物,并且不需要聚合剂。也可以将胶原基质与被聚合剂活化的纤维蛋白原溶液一起使用,于是得到混合的基质。
当使用其他可生物降解的化合物形成基质时,也可不必需使用聚合剂。例如,可以选择琼脂糖溶液,该溶液在39-42℃时为液体基质溶液,而在35-38℃时变成固体(即凝胶状)。琼脂糖也应具有一定的浓度,使得填充至软骨缺损处的凝胶具有一定的筛目大小,因此使修复细胞自由地聚居于基质和缺损区域中。
在本发明的组合物中,可以向基质溶液中加入一种或多种增殖(促有丝分裂)剂。增殖剂应该以合适的浓度范围存在,使其对填充于缺损处的基质中的修复细胞具有增殖作用(见实施例)。优选的是,同一增殖剂还对细胞具有趋化作用(例如TGF-β);但是,仅仅具有增殖作用的因子也可以使用。或者,为了在产生趋化性细胞迁移后诱导细胞增殖,可以使用两种不同的试剂,每种试剂仅具有其中一种特定的作用(或者是趋化性或者是增殖)。
适用于本发明组合物和方法以刺激修复细胞增殖的增殖(促有丝分裂)剂包括转化生长因子(“TGFs”)例如TGF-αS和TGF-βS;类胰岛素生长因子(“IGF I”);酸性或碱性成纤维细胞生长因子(“FGFs”) ;血小板衍生的生长因子(“PDGF”);表皮生长因子(“EGF”)和造血生长因子例如白细胞介素3(“IL-3”)〔Rizzino,1987,上文;Canalis等人,上文,1988;Growth factors inbiology and medicine,Ciba  FoundationSymposium,116(New York:John Wiley &Sons,1985);Baserg a,R.,ed.,Cell growthand division(Oxford:IRL Press,1985);Sporn,M.A.和Roberts,A.B.,eds.,Peptidegrowth factors and their receptors.Vols.I和II(Berlin:Springer-Verlag,1990)〕。但是,这些具体的例子并非是限制。正如体外细胞增殖分析所证实的,任何能够刺激细胞增殖的化合物或组合物都可用于本发明作增殖剂。这些分析方法是本领域已知的〔例如Canalis等人,1988,上文;Gimenez-Gallego等人,1986,上文;Dickson等人,1987,上文; Rizzino,1987,上文〕。
适用于本发明组合物和方法以吸引修复细胞的趋化剂包括例如TGF-βs、FGFs(酸或碱)、PDGF、肿瘤坏死因子(例如TNF-α、TNF-β)和蛋白多糖降解产物,例如葡糖氨聚糖链〔Roberts等人,(1990),上文;Growth factorsin biology and.medicine.Ciba FoundationSymposium,116(New York,John Wiley &Sons,1985);R.Baserga,ed.,Cell growthand division(Oxford:IRL Press,1985)〕。测定多肽和其他化合物趋化性能力的分析方法是本领域已知的〔例如Postlewaite等人,1987,上文;Wahl等人,1987,上文;Moore等人,1989,上文〕。
在本发明优选的具体例子中,基质含有TGF-β作为增殖剂和趋化剂。特别是,TGF-βI或TGF-βII可以用作增殖剂和趋化剂。其他TGF-β形式(例如TGF-βIII、TGF-βIV、TGF-βV等)或具有TGF-β活性的多肽〔见Roberts,1990,上文〕也可用于此目的,还有将来被发现的该物质的其他形式,以及其他生长因子。为了用作增殖剂和趋化剂,将TGF-β分子溶解或悬浮于基质中,其浓度优选为2-50ng/ml基质溶液,最优选2-10ng/ml基质溶液。很显然,刺激修复细胞增殖的TGF-β的优选浓度可以随着接受治疗的具体动物变化。
在基质中还可以存在转化因子,以便在修复细胞聚居于基质中后,转化因子将以足以促进修复细胞分化(即转化)成为软骨细胞,由软骨细胞形成新的稳定的软骨组织的浓度释放至缺损部位。如果转化因子能够抑制或干扰增殖剂的效果,那么适当控制转化因子的释放速度是特别重要的〔见Roberts等人(1990),上文〕。
适用于本发明组合物和方法的转化因子包括能诱导修复细胞分化成软骨细胞,从而产生特异的软骨蛋白多糖和II型胶原的任何肽、多肽、蛋白质或任何其他化合物或组合物。化合物或组合物在细胞中诱导或刺激特异的软骨蛋白多糖和II型胶原产生的能力可以用本领域已知的分析方法测定〔例如Seyedin等人,1985,上文;Seyedin等人,1987,上文〕。适用于本发明组合物和方法的转化因子包括例如TGF-βs、TGF-αs和FGFs(酸或碱)。这些转化因子可以单独或混合使用。另外,TGF-β可以与EGF结合使用。
适当控制转化因子的释放速度可以通过将转化因子包裹或结合在合适的传送系统中来实现。适用于本发明组合物和方法的传送系统包括脂质体、bioerodible聚合物、碳水化合物骨架微粒、纤维(例如与肝素硫酸蛋白多糖或其他这类分子化学联接的胶原,转化因子能自动与其粘结)、以及渗透泵。传送系统例如与转化因子结合的脂质体、bioerodible聚合物、纤维和含有转化因子的碳水化合物骨架微粒可以与用于填充缺损的基质溶液混合。这些系统是本领域已知的和市售的〔见P.Johnson和J.G.Lloyd-Jones,eds.,Drug Delivery Systems(Chichester,England:Ellis Horwood Ltd.,(1987)〕。脂质体可以按照Kim等人所述方法制备(Biochem.Biophys.Acta,728,第339-348页,(1983))。也可以使用其他脂质体制备方法。刺激软骨细胞合成软骨组织成分的附加因子可以和转化因子一起包括在传送系统中。
在本发明优选的具体例子中,基质含有TGF-β作为增殖剂和趋化剂,并且含有包裹在传送系统中的TGF-β作为转化因子。特别是,TGF-βI或TGF-βII可以同时用作增殖剂、趋化剂和转化因子。其他TGF-β形式(例如TGF-βIII、TGF-βIV、TGF-βV等)或具有TGF-β活性的多肽(见Roberts,1990,上文),还有在将来被发现的该物质的其他形式和其他生长因子均可以用于此目的。
在优选的具体例子中,用作增殖剂和趋化剂的TGF-β的浓度优选为2-50ng/ml基质溶液,最优选的是2-10ng/ml基质溶液。在基质组合物中,高得多的浓度的TGF-β作为转化因子以可随后释放的形式存在。优选的是,TGF-β的随后浓度大于200ng/ml基质,最优选的是大于500ng/ml基质。很显然,诱导修复细胞分化的TGF-β的优选浓度随被治疗的具体动物而变化。
由于TGF-β在较高浓度时(例如大于200ng/ml基质溶液),不仅仅将修复细胞转化成为软骨细胞,还将抑制修复细胞的趋化性吸引;而当TGF-β在较低浓度时(例如2-10ng/ml),TGF-β不仅吸引修复细胞并刺激它们增殖,而且还不能诱导修复细胞转化成产生软骨组织的软骨细胞,所以必需错开修复细胞暴露于两种浓度TGF-β中的时间。
在本发明优选的具体例子中,为了获得顺序趋化和增殖,然后转化TGF-β以游离的、未包裹的和包裹的两种形式存在,或者在基质中以其他隔离的形式存在。优选的是,为了吸引并诱导基质和缺损区域中的修复细胞增殖,将TGF-β分子以2-10ng/ml基质溶液的浓度溶解或悬浮于基质中。为了促进基质中的修复细胞转化成软骨细胞,也按照Kim等人所述的方法(1983,上文)将TGF-β分子以隔离在多囊脂质体中的形式存在于基质中,其浓度大于200ng/ml基质溶液,优选的浓度大于500ng/ml。当所吸引的修复细胞聚居于基质中并开始降解基质时,载有TGF-β的脂质体就破裂了。在基质的降解过程中,修复细胞摄入和/或降解脂质体,导致TGF-β以足以诱导修复细胞转化成软骨细胞的浓度释放。
通过转化浓度的TGF-β与可生物侵蚀聚合物混合,也可以实现趋化性、增殖所需TGF-β浓度与转化所需的TGF-β浓度的两阶段释放。或者,也可以用泵,特别是植入的渗透泵来控制TGF-β在缺损处和基质中的浓度。在本发明的此具体例子中,泵控制TGF-β在基质中的浓度,即泵在开始时以趋化性和增殖刺激浓度释放TGF-β,随后以转化浓度释放TGF-β。优选的是,转化浓度的TGF-β在手术后大约1-2周被泵释放。转化因子释放至缺损体积最好集中于缺损部位的基质中。
本发明组合物中的增殖剂以及转化因子(当使用时)在可生物降解基质中施用于缺损部位。因此它们被限制存在于非常集中的部位。这样做就避免了它们游离注射或输注到关节空间中。这种游离输注会产生副作用,刺激滑膜细胞产生关节渗漏。
Fibronectin或含有氨基酸序列Arg-Gly-Asp的任何其他化合物,包括象四肽这样小的肽,也可以用作细胞粘附促进因子〔Ruoslathi等人,1986,上文〕以促进修复细胞开始粘附在沉积于缺损部位的基质中。纤维蛋白和某些胶原基质已经含有该序列〔Ruoslathi等人,1986,上文〕。当使用其他可生物降解基质时,在基质用于敷裹缺损之前,这些细胞粘附促进因子可以与基质材料混合。含有Arg-Gly-Asp的肽也可以化合偶合到基质材料(例如其纤维或网状结构)上,或者偶合到基质中的化合物例如白蛋白上。
前面所述的组合物适用于在动物的软骨组织中缺损或损伤的选择性部位诱导软骨形成的方法。
本发明的方法可以用于治疗动物包括人的软骨缺损,该方法使用简单并且被限制集中于受侵袭的关节区域。可以在单一独一个的关节镜或开放性外科术中进行全部治疗。
为了实施本发明的治疗软骨缺损或损伤的方法,要对缺损或损伤进行鉴定、制备和敷用本发明的可生物降解基质组合物。在基质组合物中含有适当浓度的增殖(促有丝分裂)剂,以刺激基质和缺损或损伤处的修复细胞增殖。只要所使用的因子对细胞增殖和趋化性具有综合作用,就可以使用此浓度的同一试剂作为趋化剂以吸引修复细胞(例如浓度为2-10ng/ml基质的TGF-β)。或者,可以在基质中存在两种不同的试剂,一种具有特定的增殖作用,另一种具有特定的趋化作用。或者在另一个具体例子中,当缺损区域用可生物降解的基质敷裹后,可以将增殖剂,以及如果需要将趋化剂直接注射到基质填充的缺损区域。
在随后的步骤中,将基质中的修复细胞暴露于转化因子中适当的时间,转化因子的浓度足以使修复细胞转化成为产生稳定的软骨组织的软骨细胞。这可以通过在上述基质组合物中包括一种含有转化因子的合适的传送系统来实现。或者,可以在合适的时间通过直接注射来传送转化剂到基质填充的缺损区域。转化剂的浓度应该制成在可生物降解基质开始植入缺损区域后的1-2周使细胞可得到。附加因子可以加到传送系统中或者直接注射以更好地促进此时间点的软骨基质成分合成。
在关节的关节镜检查过程中或者在简单的开放式外科术检查损伤或缺损过程中,动物软骨缺损或损伤很容易通过肉眼识别。软骨缺损还可以通过使用计算机辅助照相术(CAT扫描)、X射线检查、磁共振成像(MRI)、滑液或血清标记分析或者通过任何本领域已知的其他方法推断识别。
一旦识别出缺损,外科医生可以选择外科手术修饰缺损,以提高缺损物理保留上述治疗方法中所加入的溶液和基质材料的能力。优选的是,为了更好地保留上述治疗方法中所加入的溶液和基质材料,缺损不应是扁平的或浅凹面的几何形状,而是具有或形成垂直的边缘或者是倒凹的。
除了上述改善基质粘附到缺损部位的机械方法之外,化学方法也可以促进基质粘附。这些方法包括使缺损表面上软骨蛋白多糖的表面层降解而将软骨的胶原原纤维暴露出来,这样它们就可以与基质中的胶原原纤维(当使用胶原基质时)或者与基质中的纤维蛋白原纤维(当使用纤维蛋白基质时)相互作用。软骨表面的蛋白多糖不仅仅趋于干扰纤维蛋白或其他可生物降解基质对软骨的粘附,还将局部抑制凝血酶的活性。有利的是,蛋白多糖降解产物还可以对修复细胞具有趋化作用〔Moore,A.R.等人,Int,J.Tiss.Reac.,XI(6)第301-307页(1989)〕。
此外,基质对缺损软骨的粘附还可以通过使用纤维蛋白兰(即血液因子XIII或纤维蛋白稳定因子)促进基质中原纤维与缺损表面上软骨胶原原纤维的结合(交联)来提高〔见Gibble等人,Transfusion,30(8),第741-47(1990)〕。谷氨酰胺转移酶也可用于相同的作用〔见例如Ichinose等人,J.Biol.Chem.,265(23),第13411-14(1990);“Transglutaminase”,Eds:V.A.Najjar和L.Lorand,Martinus Nijhoff Publishers(Boston,1984)〕。还可以使用能促进胞外物质粘附的其他化合物。
本发明方法的一个具体例子是,通过用灭菌吸收纸吸收缺损区域使缺损表面干燥,并用灭菌酶溶液填充缺损体积2-10分钟使软骨表面存在的蛋白多糖降解,并定位在缺损表面的约1-2μm深。各种酶可以在灭菌缓冲含水溶液中单独或混合使用,使蛋白多糖降解。溶液的PH值应调节至最佳酶活性。
在本发明方法中适用于降解蛋白多糖的酶包括软骨素酶(Chondroitinase)ABC、软骨素酶AC、透明质酸酶、胃蛋白酶、胰蛋白酶、糜蛋白酶、木瓜蛋白酶、链霉蛋白酶、stromelysin和Staph V8蛋白酶。具体的酶或酶混合物的合适浓度取决于该酶溶液的活性。
在本发明优选的具体例子中,用浓度为1μ/ml的软骨素ABC的灭菌溶液填充缺损,并使其消化4分钟。通过用电子显微镜检测兔关节软骨组织决定优选的软骨素酶ABC的浓度,该组织已经按照实施例1所述方法用各种浓度的酶处理不同的时间。所使用的任何其他的酶都应该以一定浓度在一定时间内使用,使得只有约1-2μm深的表面蛋白多糖被降解。
酶溶液施用的时间应保持在最小量,使其主要在修复区域影响蛋白多糖的降解。对于浓度为1μ/ml的软骨素酶ABC,消化时间超过10分钟会导致缺损区域以外的蛋白多糖不必要的和潜在有害的降解。而且,消化时间超过10分钟会使整体操作时间过长。整体操作时间应保持在最小,特别是在开放性关节切开术过程中,因为软骨暴露在空气中会受到损伤〔Mitchell等人,(1989),上文〕。由于这些原因,在包括了通过酶消化使蛋白多糖降解步骤的本发明方法的具体例子中,推荐消化时间少于10分钟,最优选的是消化时间少于5分钟。
按照本发明的方法,在酶使缺损表面的蛋白多糖降解之后,应该将酶溶液从缺损区域除去。通过使用装有细吸气顶端的吸气器后在用具有棉花的海绵吸收,可以有效地除去酶溶液。或者,可以只用棉花吸收除去酶溶液。
除去酶溶液后,应该用灭菌生理盐水(例如0.15M NaCl)彻底清洗缺损处,最好洗三次。然后应该将清洗过的缺损部位干燥。可以用无菌纱布或棉花对缺损部位进行干燥。
或者,除了酶处理步骤之外,还可以用化合物例如纤维蛋白胶或谷氨酰胺转移酶敷裹缺损部位,以促进基质对缺损部位的粘附。在优选的具体例子中,将纤维蛋白胶或谷氨酰胺转移酶施用于酶处理后经清洗和干燥后的缺损部位。
按照本发明的方法,然后用本文所述的本发明组合物敷裹缺损部位,以填充缺损,优选用基质组合物填充其边缘,使得形成扁平的平面。该组合物含有一种基质材料和一种增殖剂,以及如果需要,含有一种趋化剂。此步骤中使用的组合物还可以含有包裹在合适传送系统中的一种转化因子。在本发明最优选的方法中,基质含有一种增殖剂,一种趋化剂(它可以和增殖剂不同)和包裹或结合在传送系统中的一种转化因子,该转化因子在一定时间(此时聚居于基质中的修复细胞开始改造胞间物质)以一定浓度(该浓度可以将修复细胞转化成为软骨细胞释放。上述组合物是优选的。
如果基质不含增殖剂和趋化剂,为了传送优选的浓度以促进修复细胞的趋化性和增殖,可以将上述试剂直接注射到基质填充的缺损区域。在本发明的此具体例子中,优选的是,在用基质敷裹缺损后,将TGF-β局部注射到基质中,得到2-10ng/ml基质的浓度。注射应该集中在基质填充的缺损区域中,以避免滑膜细胞暴露在生长因子中,导致细胞增殖和关节渗漏。
在用基质组合物敷裹缺损部位后(以及,就纤维蛋白基质来说,一旦基质已经固化)并且如果需要,将增殖剂注射到基质填充的缺损部位后,关节囊和皮肤切口就可以关闭,关节镜检查或开放式外科术就可以终止了。
如果在合适传送系统的基质中不含有转化因子,那么在手术后大约1-2周,可以将转化因子直接加入到基质中,例如通过注射或通过渗透泵,其浓度足以将修复细胞转化成软骨细胞。优选的是,在本发明的该具体例子中,在手术后大约1周时直接将TGF-β加入到基质中,得到大于200ng/ml基质的浓度,最优选的是浓度大于500ng/ml基质。
当缺损没有延伸到软骨下的骨头时,本文所述的修复关节软骨缺损的方法是最有效的。本文所述的方法也可以用于修复半月板软骨组织缺损。
为了更充分地理解本文所述的发明,举出下列实施例。应该理解,这些实施例是用于说明本发明,而不是对本发明任何方式的限制。
                       实施例1
                 蛋白多糖迁移的酶试验
为了促进和改善基质沿着关节软骨组织的表面缺损表面粘附,可以使表面软骨基质中的蛋白多糖分子酶促迁移,以使胶原纤维网络暴露在外部施用的基质中并使修复细胞迁移。各种蛋白酶和葡糖氨多糖降解酶也适用于此目的,但是应该控制PH值,使各种酶具有最大的活性。
在此实施例中,我们对软骨素酶ABC(0.5-5μ/ml)和胰蛋白酶(0.5-4%)影响蛋白多糖迁移的能力进行了试验。使用从当地屠夫处获得的刚宰杀兔的膝关节。将机械产生的表面软骨缺损暴露在酶溶液中4分钟。然后用吸收纸除去溶液,并用生理盐水清洗缺损部位。完成此过程后,将软骨组织立刻在含有0.7%(w/v)六胺三氯化钌(RHT)的2%(v/v)戊二醛溶液(用0.05M卡可酸钠缓冲,PH7.4)固定,进行组织检查。固定后的介质含有1%RHT-四氧化锇溶液(用0.1M卡可酸钠缓冲)。将组织在梯度系列乙醇中脱水并包埋在Epon812中。将组织制成薄切片,用乙酸双氧铀和柠檬酸铅染色,并用电子显微镜检查。在这些切片中,RHF固定的(即沉淀的)蛋白多糖呈现为黑色染色颗粒。使不超过1-2μm厚的表面层蛋白多糖迁移的酶的浓度是最佳的(酶更深的渗透会影响下面的软骨细胞)。我们发现软骨素酶ABC浓度为约1μ/ml时具有最佳活性。胰蛋白酶浓度为约2.5%时具有最佳活性。其他葡糖氨聚糖酶或蛋白酶的最佳活性范围可以用同样的方法测定。任何缓冲液,如果没有毒性并且其最大缓冲容量在接近最大酶活性所需的PH值时出现,都可以与酶一起使用。
                    实施例2
                基质对表面缺损的粘附
我们对通过控制表面软骨蛋白多糖的酶消化来促进基质沿着缺损表面粘附的可能性进行了研究。通过用整平(planing)刀切,使三只成年兔的膝关节产生缺损。这些缺损不用酶处理。用纤维蛋白基质填充缺损,该基质是在填充缺损前约200秒时将20μl凝血酶溶液(100μ/ml含水缓冲液)与每ml纤维蛋白原溶液(1mg/ml水缓冲液)混合制成的。一个月后将兔子处死,对膝关节进行检查,以测定纤维蛋白基质对缺损部位的粘附程度。将所得结果与用纤维蛋白基质填充缺损前用软骨素酶ABC(1μ/ml4分钟)治疗缺损的兔子(见实施例3、4和5)所得结果进行比较。
沉积于未用酶处理过的剩余缺损区域中的纤维蛋白基质对缺损表面的粘着具有很低的亲和力。经酶处理后,纤维蛋白基质的粘着能力(通过测量粘着的机械强度,即通过试验用镊子尖用手推动基质的容易程度测定,以及通过记录在整个实验过程中成功地保持基质粘着的缺损数目间接测定)显著增加了。基质对未用酶处理的缺损表面亲和力低可能是由于蛋白多糖分子局部抑制基质粘着以及纤维蛋白聚合受到抑制。通过将沿着缺损表面区域的表面蛋白多糖酶促迁移,可以防止上面两种作用。
               实施例3
    将生长因子施用于缺损部位以趋化性刺激修复
    细胞使之迁移到缺损区域并诱导修复细胞增殖
我们对各种生长因子刺激修复细胞趋化性迁移至缺损区域以实现治愈缺损的作用进行了试验。
所使用的生长因子包括a)表皮生长因子(EGF),b)碱性成纤维细胞生长因子(bFGF),c)类胰岛素生长因子I(IGF.I),d)人生长激素(hGH)和e)转化生长因子-β(TGF-β),其浓度为5-10ng/m l。
将每种生长因子局部施用于膝关节产生的缺损部位,该缺损部位先按照实施例2所述方法用软骨素酶ABC处理并清洗。总共使用10只动物(每种生长因子用两只)。每种生长因子能够足以趋化性地吸引或局部刺激修复细胞增殖到缺损表面,使缺损表面被全部覆盖。但是,细胞只存在于缺损表面,并且修复细胞的增殖不能填充全部缺损体积。
(据信,蛋白多糖降解产物本身,即在不需加入任何其他试剂下,就能产生足够的趋化作用,将修复细胞吸引到缺损部位。Moore,A.R.等人〔Int.J.Tiss.Reac.,XI(b),第301-107页,1989〕已证明蛋白多糖降解产物本身具有趋化作用)。
             实施例4
        将包裹在可生物降解基质中的生长因子
        施用于缺损部位以趋化性刺激修复细胞
        迁移至缺损区域并诱导修复细胞增殖
由于按照实施例3的条件局部施用生长因子不能诱导修复细胞增殖到足以填充缺损体积,因此使用同样的生长因子重复此实验,只是这次将生长因子包裹在可生物降解的基质中。所使用的可生物降解基质是纤维蛋白,胶原和琼脂糖。使用足够量的含有生长因子的基质将缺损体积完全填充。
在填充到缺损部位前约200秒时,将20μl凝血酶溶液(100μ/ml水缓冲液:佛罗那乙酸盐缓冲液,PH7.0)与每ml纤维蛋白原溶液(1mg/ml水缓冲液:0.05M TrisPH7.4,0.1M NaCl)混合制成纤维蛋白基质。如果用胶原作基质,可以用Colagen-Vliess或明胶—血液混合物制成足够粘度的溶液。如果用琼脂糖作基质,则用39-42℃的琼脂糖液体溶液填充缺损。冷却(35-38℃)后,在缺损处形成琼脂糖基质。
用30只兔子进行该实验(每种类型基质和生长因子用两只兔子)。在所有放置的基质,保持与缺损粘附的情况下缺损由成纤维细胞样的修复细胞完全聚集。这种状况早在手术后8-10天就发现了。除了可生物降解基质被修复细胞改造并且被松散的、结缔组织类型的胞外基质替代之外,在手术后4周没有进一步发现修复组织的结构组织发生改变。
该组织没有转化成为软骨组织。
                   实施例5
        将包裹在可生物降解基质中的生长因子
        施用于缺损部位以趋化性刺激修复细胞
        迁移至缺损区域并诱导修复细胞增殖
            然后在第二阶段适时地、局部释放
         转化因子以使缺损部位转化成透明软骨
在施用生长因子后,缺损体积中的基质被修复细胞完全填充,以及这些细胞能改变过沉积的基质(见实施例4)——这些发现促使我们研究引进包裹形式(例如脂质体)的转化因子(例如TGF-β)的作用,当基质完全被修复细胞聚集(该细胞开始改造胞间结构)时,转化因子就从包裹形式中释放出来。
将TGF-β以低浓度(例如2-10ng/ml)混入纤维蛋白原溶液(1mg/ml)中,以引起最初的趋化和增殖作用。TGF-β也按照Kim等人〔(1983),上文〕的方法包裹在脂质体中。将含有TGF-β的脂质体加到同样的纤维蛋白原溶液中,其浓度应该在该脂质体破裂并释放出TGF-β时足以提供较高浓度(100-1000ng/ml纤维蛋白原)的TGF-β,以便在纤维蛋白基质聚集的修复细胞开始改变胞间物质的第二阶段期间促使修复细胞转化成软骨细胞和促使基质填充的缺损转化成软骨。
按照实施例2的方法使10只成年兔的表面膝关节软骨产生缺损,通过将含有游离的和脂质体包裹的TGF-β的纤维蛋白原混合物施用于缺损部位对缺损进行治疗。在这一系列实验中的各个实验中,游离TGF-β的浓度保持在2-10ng/ml纤维蛋白原的范围,同时包裹的TGF-β的浓度是变化的,以便以100ng的间隔(根据从脂质体释放TGF-β的多少)提供100-1000ngTGF-β/ml纤维蛋白原的浓度,在所有各例的治疗部位均形成透明软骨组织。在高于200ng包裹的TGF-β/ml纤维蛋白原溶液的浓度下,最好是在高于500ng TGF-β/ml纤维蛋白原溶液的浓度下得到最能复现的结果。
                     实施例6
               测定组织转化的时间点
在此实验中,按照实施例2的方法对一组6只成年兔进行膝外科术,以产生表面缺损。对表面缺损修复实施一个全面的治疗方案,即用软骨素酶ABC(1μ/ml)处理(4分钟),然后用含有游离TGF-β(约2-10ng/ml)和包裹TGF-β(约800ng/ml)的脂质体的纤维蛋白基质(1mg/ml纤维蛋白原溶液,20μl 100μ/ml凝血酶溶液/ml纤维蛋白原溶液)填充缺损部位。在手术后第8、10和12天杀死三只兔子,在20、24和28天杀死剩余的三只。在这种动物模型中,在12-20天,原始的、成纤维细胞样的修复细胞组织转化成为透明软骨组织。这是根据组织检查测定的。在8-12天,仍然存在松散的纤维性修复组织(所施用的纤维蛋白基质被部分或全部改造),而在20天及20天以后,缺损的空间被透明软骨组织部分或完全填充。
                    实施例7
           在小猪模型中使用软骨修复方法
将上面用于兔子模型的实验方法用于更大的动物模型——小猪。通过用刮刀(planing knife)在四只成年小猪(2-4龄,80-110磅)的髌骨沟和内侧髁切割,产生表面缺损(0.6mm宽,0.6mm深,10-15mm长)。然后用软骨素酶ABC处理缺损(1μ/ml,处理4分钟,按照上文对兔子使用的那样)。除去酶溶液,使缺损干燥,用生理盐水清洗,然后再干燥。然后用纤维蛋白原基质溶液填充缺损部位。用于该实验的纤维蛋白基质溶液每ml含有2-6ng游离的TGF-β,并且每ml纤维蛋白原溶液含有1500-2000ng脂质体包裹的TGF-β。在填充缺损前,按照上面兔子实验中所述方法,将凝血酶加到该基质溶液中。
手术后6周将小猪杀死,对基质填充的缺损部位进行组织检查。所有部位表明都治愈了,即在治疗部位形成了透明软骨组织。

Claims (7)

1.治疗或修复软骨缺损或损伤的组合物,该组合物含有:
选自纤维蛋白原/凝血酶、胶原、纤维蛋白、琼脂糖、Sepharose、明胶及其组合的可生物降解基质或形成基质的材料,该基质用于敷裹软骨的缺损或损伤区域,所述基质或形成基质的材料含有:
选自TGF-βs、FGFs、IGF I、PDGF、EGF、TGF-αs、人生长激素和造血生长因子的增殖剂,所述增殖剂以适当浓度存在,以刺激基质和缺损或损伤区域中的修复细胞的增殖;
选自TGF-βs、TGF-αs、FGFs、它们的组合、TGF-β与EGF的组合的转化因子,其中转化因子与传送系统结合,所述传送系统选自脂质体、可生物侵蚀的聚合物、与肝素硫酸蛋白多糖化学连接的胶原纤维和基于碳水化合物的颗粒;并且
其中转化因子以适当浓度存在,以使在转化因子传送给基质和缺损区域中的增殖的修复细胞后,该修复细胞转化成为产生软骨组织的软骨细胞。
2.如权利要求1的组合物,该组合物进一步含有适当浓度的趋化剂,以将修复细胞吸引到基质和缺损区域中,所述趋化剂选自TGF-βs、EGF、FGFs、IGF I、hGH、PDGF、TNF-α、TNF-β和蛋白多糖降解产物。
3.如权利要求2的组合物,其中增殖剂、趋化剂和转化因子都选自TGF-βs。
4.如权利要求3的组合物,其中增殖剂和趋化剂是在基质中浓度为2-50ng/ml的TGF-β,转化因子是与合适的传送系统结合的TGF-β,该系统能在基质中提供大于200ng/ml浓度的TGF-β。
5.治疗或修复软骨缺损或损伤的组合物,该组合物含有:
纤维蛋白基质,该基质是通过向纤维蛋白原溶液中加入凝血酶形成的,
以2-10ng/ml纤维蛋白原溶液的浓度存在的TGF-β,它作为增殖剂和趋化剂以刺激基质和缺损区域中的修复细胞的增殖、并将修复细胞吸引到基质和缺损区域中;和
以大于200ng/ml纤维蛋白原溶液的浓度存在的包裹在脂质体中的TGF-β,它用作转化因子,该转化因子随后被传送至增殖的修复细胞中,以将修复细胞转化成为产生软骨组织的软骨细胞。
6.如权利要求1、2或5的组合物,该组合物进一步含有含三肽Arg-Gly-Asp的细胞粘附促进因子。
7.权利要求1-6中任一项的组合物用于制备治疗软骨表面缺损的药物的用途。
CN92101431A 1991-01-31 1992-01-31 治疗及修复软骨缺损或损伤的方法及组合物 Expired - Fee Related CN1056083C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/648,274 1991-01-31
US07/648,274 US5206023A (en) 1991-01-31 1991-01-31 Method and compositions for the treatment and repair of defects or lesions in cartilage

Publications (2)

Publication Number Publication Date
CN1064813A CN1064813A (zh) 1992-09-30
CN1056083C true CN1056083C (zh) 2000-09-06

Family

ID=24600141

Family Applications (1)

Application Number Title Priority Date Filing Date
CN92101431A Expired - Fee Related CN1056083C (zh) 1991-01-31 1992-01-31 治疗及修复软骨缺损或损伤的方法及组合物

Country Status (19)

Country Link
US (2) US5206023A (zh)
EP (1) EP0569541B1 (zh)
JP (2) JPH06505258A (zh)
KR (1) KR100235391B1 (zh)
CN (1) CN1056083C (zh)
AT (1) ATE121943T1 (zh)
AU (1) AU667032B2 (zh)
CA (1) CA2101556C (zh)
DE (1) DE69202332T2 (zh)
DK (1) DK0569541T3 (zh)
ES (1) ES2072144T3 (zh)
HK (1) HK1006416A1 (zh)
IE (1) IE67515B1 (zh)
IL (1) IL100799A (zh)
NO (1) NO307735B1 (zh)
NZ (1) NZ260125A (zh)
TW (1) TW214514B (zh)
WO (1) WO1992013565A1 (zh)
ZA (1) ZA92726B (zh)

Families Citing this family (398)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023090A (en) * 1989-08-16 1991-06-11 Levin Robert H Topical compositions containing LYCD and other topically active medicinal ingredients for the treatment of ACNE
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5837539A (en) * 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US6010696A (en) * 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5811094A (en) * 1990-11-16 1998-09-22 Osiris Therapeutics, Inc. Connective tissue regeneration using human mesenchymal stem cell preparations
US6054122A (en) 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US7189410B1 (en) * 1990-11-27 2007-03-13 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6117425A (en) * 1990-11-27 2000-09-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, method of their production and use
US6197325B1 (en) 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6559119B1 (en) 1990-11-27 2003-05-06 Loyola University Of Chicago Method of preparing a tissue sealant-treated biomedical material
US6391343B1 (en) 1991-01-15 2002-05-21 Hemosphere, Inc. Fibrinogen-coated particles for therapeutic use
US5616311A (en) * 1991-01-15 1997-04-01 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
US5853746A (en) * 1991-01-31 1998-12-29 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone using functional barrier
US5206023A (en) * 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US7056882B2 (en) 1991-03-11 2006-06-06 Curis, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US5674844A (en) * 1991-03-11 1997-10-07 Creative Biomolecules, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
SE9101853D0 (sv) * 1991-06-17 1991-06-17 Jonas Wadstroem Improved tissue ashesive
US6440427B1 (en) * 1991-06-17 2002-08-27 Biovitrum Ab Tissue treatment composition comprising fibrin or fibrinogen and biodegradable and biocompatible polymer
DE4125400C2 (de) * 1991-07-31 2000-08-17 Edwin Klaus Verwendung von unlöslichem Kollagen zur Behandlung von degenerativen, nicht entzündlichen Gelenkprozessen
US5270300A (en) * 1991-09-06 1993-12-14 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
US5171579A (en) * 1991-10-11 1992-12-15 Genetics Institute, Inc. Formulations of blood clot-polymer matrix for delivery of osteogenic proteins
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
EP0625891B1 (en) * 1992-02-14 1997-01-08 Board Of Regents The University Of Texas System Multi-phase bioerodible implant/carrier and method of manufacturing and using same
CA2093836A1 (en) * 1992-04-24 1993-10-25 Wayne Gombotz Biodegradable tgf-.beta. delivery system for bone regeneration
IL105529A0 (en) * 1992-05-01 1993-08-18 Amgen Inc Collagen-containing sponges as drug delivery for proteins
CA2103943A1 (en) * 1992-08-21 1994-02-22 A. Gregory Bruce Composition and methods for the generation of bone
CN1091315A (zh) * 1992-10-08 1994-08-31 E·R·斯奎布父子公司 血纤维蛋白封闭剂组合物及其使用方法
US5320102A (en) * 1992-11-18 1994-06-14 Ciba-Geigy Corporation Method for diagnosing proteoglycan deficiency in cartilage based on magnetic resonance image (MRI)
ES2225828T3 (es) * 1993-03-12 2005-03-16 The American National Red Cross Sellantes de tejido suplementados, procedimientos de produccion y uso.
US5549904A (en) * 1993-06-03 1996-08-27 Orthogene, Inc. Biological adhesive composition and method of promoting adhesion between tissue surfaces
US5368051A (en) * 1993-06-30 1994-11-29 Dunn; Allan R. Method of regenerating articular cartilage
US5916557A (en) * 1993-11-12 1999-06-29 The Trustees Of Columbia University In The City Of New York Methods of repairing connective tissues
AU1176595A (en) * 1993-11-12 1995-05-29 International Technology Management Associates, Ltd. Methods of repairing connective tissues
US5591625A (en) * 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
WO1995022316A1 (en) * 1994-02-17 1995-08-24 New York Blood Center, Inc. Biologic bioadhesive compositions containing fibrin glue and liposomes, methods of preparation and use
CA2187353C (en) * 1994-04-08 2007-05-22 Gerald L. Yewey Liquid delivery compositions
US5644026A (en) * 1994-05-03 1997-07-01 La Jolla Cancer Research Foundation Epitaxin, a cell motility factor
WO1995030742A1 (en) * 1994-05-05 1995-11-16 Genzyme Corporation Methods and compositions for the repair of articular cartilage defects in mammals
US5723331A (en) * 1994-05-05 1998-03-03 Genzyme Corporation Methods and compositions for the repair of articular cartilage defects in mammals
US6017891A (en) * 1994-05-06 2000-01-25 Baxter Aktiengesellschaft Stable preparation for the treatment of blood coagulation disorders
US5906827A (en) * 1994-06-03 1999-05-25 Creative Biomolecules, Inc. Matrix for the manufacture of autogenous replacement body parts
DK0952792T3 (da) * 1994-06-06 2003-12-08 Osiris Therapeutics Inc Biomatrix til vævsregeneration
JPH07328108A (ja) * 1994-06-10 1995-12-19 Ajinomoto Co Inc 生体組織接着剤及び血液凝固剤
US8603095B2 (en) 1994-09-02 2013-12-10 Puget Bio Ventures LLC Apparatuses for femoral and tibial resection
US6695848B2 (en) 1994-09-02 2004-02-24 Hudson Surgical Design, Inc. Methods for femoral and tibial resection
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US6911216B1 (en) * 1994-10-12 2005-06-28 Genzyme Corporation Targeted delivery via biodegradable polymers
EP0785774B1 (en) * 1994-10-12 2001-01-31 Focal, Inc. Targeted delivery via biodegradable polymers
CA2207289C (en) * 1994-12-07 2005-04-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US5585007A (en) 1994-12-07 1996-12-17 Plasmaseal Corporation Plasma concentrate and tissue sealant methods and apparatuses for making concentrated plasma and/or tissue sealant
US20050186673A1 (en) * 1995-02-22 2005-08-25 Ed. Geistlich Soehne Ag Fuer Chemistrie Industrie Collagen carrier of therapeutic genetic material, and method
GB9503492D0 (en) * 1995-02-22 1995-04-12 Ed Geistlich S Hne A G F R Che Chemical product
IL112834A (en) * 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US5693341A (en) * 1995-03-16 1997-12-02 Collagen Corporation Affinity bound collagen matrices for the delivery of biologically active agents
US5658588A (en) * 1995-03-31 1997-08-19 University Of Cincinnati Fibrinogen-coated liposomes
US6638912B2 (en) 1995-05-01 2003-10-28 The Regents Of The University Of California Peptide compositions mimicking TGF-β activity
US5661127A (en) * 1995-05-01 1997-08-26 The Regents Of The University Of California Peptide compositions with growth factor-like activity
US5780436A (en) * 1995-05-01 1998-07-14 The Regents Of The University Of California Peptide compositions with growth factor-like activity
US5655546A (en) * 1995-06-07 1997-08-12 Halpern; Alan A. Method for cartilage repair
US7112320B1 (en) 1995-06-07 2006-09-26 Andre Beaulieu Solid wound healing formulations containing fibronectin
US6528483B2 (en) 1995-06-07 2003-03-04 André Beaulieu Method of producing concentrated non-buffered solutions of fibronectin
US6482231B1 (en) * 1995-11-20 2002-11-19 Giovanni Abatangelo Biological material for the repair of connective tissue defects comprising mesenchymal stem cells and hyaluronic acid derivative
EP0871763B1 (en) * 1996-01-05 2009-02-25 Autoimmune, Inc. Method for preparation of type ii collagen
US5842477A (en) * 1996-02-21 1998-12-01 Advanced Tissue Sciences, Inc. Method for repairing cartilage
US6221854B1 (en) 1996-03-05 2001-04-24 Orquest, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
US20110207666A1 (en) * 1996-03-05 2011-08-25 Depuy Spine, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
US5942499A (en) * 1996-03-05 1999-08-24 Orquest, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
US6645945B1 (en) 1996-03-05 2003-11-11 Depuy Acromed, Inc. Method of treating diseased, injured or abnormal cartilage with hyaluronic acid and growth factors
US6008013A (en) * 1996-07-05 1999-12-28 University Of Rochester Chondrocyte proteins
WO1998004681A2 (en) * 1996-07-25 1998-02-05 Genzyme Corporation Chondrocyte media formulations and culture procedures
US8716227B2 (en) 1996-08-23 2014-05-06 Cook Biotech Incorporated Graft prosthesis, materials and methods
CA2263421C (en) * 1996-08-23 2012-04-17 William A. Cook Graft prosthesis, materials and methods
US6666892B2 (en) * 1996-08-23 2003-12-23 Cook Biotech Incorporated Multi-formed collagenous biomaterial medical device
US6569172B2 (en) * 1996-08-30 2003-05-27 Verigen Transplantation Service International (Vtsi) Method, instruments, and kit for autologous transplantation
US5759190A (en) * 1996-08-30 1998-06-02 Vts Holdings Limited Method and kit for autologous transplantation
US5989269A (en) * 1996-08-30 1999-11-23 Vts Holdings L.L.C. Method, instruments and kit for autologous transplantation
US20060025786A1 (en) * 1996-08-30 2006-02-02 Verigen Transplantation Service International (Vtsi) Ag Method for autologous transplantation
US20020173806A1 (en) * 1996-08-30 2002-11-21 Verigen Transplantation Service International (Vtsi) Ag Method for autologous transplantation
US7534263B2 (en) 2001-05-25 2009-05-19 Conformis, Inc. Surgical tools facilitating increased accuracy, speed and simplicity in performing joint arthroplasty
US10085839B2 (en) 2004-01-05 2018-10-02 Conformis, Inc. Patient-specific and patient-engineered orthopedic implants
US8234097B2 (en) * 2001-05-25 2012-07-31 Conformis, Inc. Automated systems for manufacturing patient-specific orthopedic implants and instrumentation
US8556983B2 (en) 2001-05-25 2013-10-15 Conformis, Inc. Patient-adapted and improved orthopedic implants, designs and related tools
US8882847B2 (en) 2001-05-25 2014-11-11 Conformis, Inc. Patient selectable knee joint arthroplasty devices
US8545569B2 (en) 2001-05-25 2013-10-01 Conformis, Inc. Patient selectable knee arthroplasty devices
US20070233269A1 (en) * 2001-05-25 2007-10-04 Conformis, Inc. Interpositional Joint Implant
US8771365B2 (en) 2009-02-25 2014-07-08 Conformis, Inc. Patient-adapted and improved orthopedic implants, designs, and related tools
US8735773B2 (en) 2007-02-14 2014-05-27 Conformis, Inc. Implant device and method for manufacture
US7468075B2 (en) * 2001-05-25 2008-12-23 Conformis, Inc. Methods and compositions for articular repair
US8083745B2 (en) * 2001-05-25 2011-12-27 Conformis, Inc. Surgical tools for arthroplasty
US7618451B2 (en) * 2001-05-25 2009-11-17 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools facilitating increased accuracy, speed and simplicity in performing total and partial joint arthroplasty
US8480754B2 (en) 2001-05-25 2013-07-09 Conformis, Inc. Patient-adapted and improved articular implants, designs and related guide tools
US8617242B2 (en) 2001-05-25 2013-12-31 Conformis, Inc. Implant device and method for manufacture
US9603711B2 (en) 2001-05-25 2017-03-28 Conformis, Inc. Patient-adapted and improved articular implants, designs and related guide tools
US20020098222A1 (en) 1997-03-13 2002-07-25 John F. Wironen Bone paste
EP0989855A4 (en) * 1997-05-13 2002-06-12 Osiris Therapeutics Inc REGENERATION OF CARTILAGE IN OSTEOARTHRITIS BY MEANS OF HUMAN MESENCHYMAL STEM CELLS
JP4132089B2 (ja) 1997-05-30 2008-08-13 オステオバイオロジックス,インコーポレイテッド 繊維強化多孔性生体分解性移植デバイス
US7524335B2 (en) * 1997-05-30 2009-04-28 Smith & Nephew, Inc. Fiber-reinforced, porous, biodegradable implant device
US6420519B1 (en) 1997-07-21 2002-07-16 The Board Of Trustees Of The University Of Illinois Modifying tissue surfaces by liquid crystal formation
ES2320603T3 (es) 1997-07-30 2009-05-25 Emory University Sistemas de expresion, vectores, adn, proteinas de mineralizacion osea novedosos.
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
AUPO832597A0 (en) * 1997-07-30 1997-08-21 Cardiac Crc Nominees Pty Limited Wound treatment compositions
US6025327A (en) * 1997-08-08 2000-02-15 Biocell Technology, Llc Hydrolyzed collagen type II and use thereof
ATE220564T1 (de) * 1997-08-14 2002-08-15 Sulzer Innotec Ag Zusammensetzung und vorrichtung zur reparatur von knorpelgewebe in vivo bestehend aus nanokapseln mit osteoinduktiven und/oder chondroinduktiven faktoren
US6511958B1 (en) 1997-08-14 2003-01-28 Sulzer Biologics, Inc. Compositions for regeneration and repair of cartilage lesions
US6306432B1 (en) * 1997-09-08 2001-10-23 Chiron Corporation High and low load formulations of IGF-I in multivesicular liposomes
US9034315B2 (en) * 1997-10-10 2015-05-19 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Cell-charged multi-layer collagen membrane
US20030180263A1 (en) * 2002-02-21 2003-09-25 Peter Geistlich Resorbable extracellular matrix for reconstruction of bone
US20050186283A1 (en) * 1997-10-10 2005-08-25 Ed. Geistlich Soehne Ag Fuer Chemistrie Industrie Collagen carrier of therapeutic genetic material, and method
US8858981B2 (en) * 1997-10-10 2014-10-14 Ed. Geistlich Soehne Fuer Chemistrie Industrie Bone healing material comprising matrix carrying bone-forming cells
GB9721797D0 (en) * 1997-10-14 1997-12-17 Univ Cardiff Materials and methods relating to cartilage repair
US6197586B1 (en) 1997-12-12 2001-03-06 The Regents Of The University Of California Chondrocyte-like cells useful for tissue engineering and methods
US6762336B1 (en) 1998-01-19 2004-07-13 The American National Red Cross Hemostatic sandwich bandage
WO1999044533A1 (en) 1998-03-06 1999-09-10 Crosscart, Inc. Soft tissue xenografts
US6972041B1 (en) 1998-03-16 2005-12-06 Crosscart, Inc. Bone xenografts
US6383732B1 (en) 1999-02-11 2002-05-07 Crosscart, Inc. Method of preparing xenograft heart valves
US20030147860A1 (en) 2002-02-07 2003-08-07 Marchosky J. Alexander Compositions and methods for forming and strengthening bone
JP2002510646A (ja) * 1998-04-03 2002-04-09 カイロン コーポレイション 関節軟骨障害を処置するためのigfiの使用
US6835377B2 (en) 1998-05-13 2004-12-28 Osiris Therapeutics, Inc. Osteoarthritis cartilage regeneration
US7252818B2 (en) 1998-07-24 2007-08-07 Cardiovascular Biotherapeutics, Inc. Method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
YU12201A (sh) * 1998-08-14 2005-06-10 Verigen Transplantation Service International (Vtsi) Ag. Metodi, instrumenti i materijali za transplantaciju ćelija hondrocita
DE19841698A1 (de) * 1998-09-11 2000-03-16 Curative Technologies Gmbh Wachstumsfaktor-enthaltende Zusammensetzung zur Heilung von Gewebeschäden
CA2354525A1 (en) 1998-09-14 2000-06-22 Stanford University Assessing the condition of a joint and preventing damage
US7184814B2 (en) * 1998-09-14 2007-02-27 The Board Of Trustees Of The Leland Stanford Junior University Assessing the condition of a joint and assessing cartilage loss
US7239908B1 (en) 1998-09-14 2007-07-03 The Board Of Trustees Of The Leland Stanford Junior University Assessing the condition of a joint and devising treatment
US6630457B1 (en) 1998-09-18 2003-10-07 Orthogene Llc Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same
MXPA01003538A (es) * 1998-10-06 2005-09-08 Rush Presbyterian St Luke Metodo para el tratamiento de quimionucleolisis.
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US6110484A (en) * 1998-11-24 2000-08-29 Cohesion Technologies, Inc. Collagen-polymer matrices with differential biodegradability
DK1051116T3 (da) 1998-12-01 2009-02-02 Univ Washington Emboliseringsanordning
US8882850B2 (en) * 1998-12-01 2014-11-11 Cook Biotech Incorporated Multi-formed collagenous biomaterial medical device
EP1141014B1 (en) 1999-01-06 2004-12-08 Genentech, Inc. Insulin-like growth factor (igf) i mutant variant
KR100704537B1 (ko) * 1999-02-01 2007-04-09 제네틱스 인스티튜트, 엘엘씨 관절 연골의 치유 및 회복을 위한 조성물
US6267786B1 (en) * 1999-02-11 2001-07-31 Crosscart, Inc. Proteoglycan-reduced soft tissue xenografts
JP2002537022A (ja) * 1999-02-16 2002-11-05 ズルツァー バイオロジクス インコーポレイテッド 軟骨病変を再生して修復する装置及び方法
US6197061B1 (en) * 1999-03-01 2001-03-06 Koichi Masuda In vitro production of transplantable cartilage tissue cohesive cartilage produced thereby, and method for the surgical repair of cartilage damage
JP2002539172A (ja) 1999-03-17 2002-11-19 ノバルティス アクチエンゲゼルシャフト Tgf−ベータを含む医薬組成物
US20040059416A1 (en) * 1999-06-22 2004-03-25 Murray Martha M. Biologic replacement for fibrin clot
AU5754800A (en) * 1999-06-22 2001-01-09 Brigham And Women's Hospital Biologic replacement for fibrin clot for intra-articular use
US6964685B2 (en) 1999-06-22 2005-11-15 The Brigham And Women's Hospital, Inc. Biologic replacement for fibrin clot
CA2378880C (en) * 1999-07-21 2010-02-23 Omeros Medical Systems, Inc. Solutions and methods for inhibition of pain, inflammation and cartilage degradation
US6179840B1 (en) 1999-07-23 2001-01-30 Ethicon, Inc. Graft fixation device and method
US20020095157A1 (en) * 1999-07-23 2002-07-18 Bowman Steven M. Graft fixation device combination
US20020116063A1 (en) * 1999-08-02 2002-08-22 Bruno Giannetti Kit for chondrocyte cell transplantation
US6579469B1 (en) 1999-10-29 2003-06-17 Closure Medical Corporation Cyanoacrylate solutions containing preservatives
EP1099443A1 (en) 1999-11-11 2001-05-16 Sulzer Orthopedics Ltd. Transplant/implant device and method for its production
US6623963B1 (en) 1999-12-20 2003-09-23 Verigen Ag Cellular matrix
US20030095993A1 (en) * 2000-01-28 2003-05-22 Hanne Bentz Gel-infused sponges for tissue repair and augmentation
CA2402191C (en) 2000-03-24 2012-03-13 Genentech, Inc. Use of insulin for the treatment of cartilagenous disorders
US6723335B1 (en) * 2000-04-07 2004-04-20 Jeffrey William Moehlenbruck Methods and compositions for treating intervertebral disc degeneration
CA2405345C (en) 2000-04-25 2012-09-18 Osiris Therapeutics, Inc. Joint repair using mesenchymal stem cells
AU2001255767A1 (en) * 2000-04-28 2001-11-12 Curis, Inc. Methods and reagents for tissue engineering of cartilage in vitro
US6645485B2 (en) * 2000-05-10 2003-11-11 Allan R. Dunn Method of treating inflammation in the joints of a body
WO2001087323A2 (en) 2000-05-16 2001-11-22 Genentech, Inc. Method for treating cartilage disorders
DE10026480A1 (de) * 2000-05-29 2001-12-13 Augustinus Bader Verfahren zur Herstellung eines empfängerspezifischen Gewebe-Transplantats oder -Implantats
WO2002017955A1 (en) * 2000-08-30 2002-03-07 University Of Delaware Delivery system for heparin-binding growth factors
ATE426357T1 (de) 2000-09-14 2009-04-15 Univ Leland Stanford Junior Beurteilung des zustandes eines gelenkes und planung einer behandlung
ES2304401T3 (es) 2000-10-16 2008-10-16 Genentech, Inc. Metodos de tratamiento que utilizan polipeptidos wisp.
US6648911B1 (en) 2000-11-20 2003-11-18 Avantec Vascular Corporation Method and device for the treatment of vulnerable tissue site
US6599323B2 (en) * 2000-12-21 2003-07-29 Ethicon, Inc. Reinforced tissue implants and methods of manufacture and use
US6852330B2 (en) 2000-12-21 2005-02-08 Depuy Mitek, Inc. Reinforced foam implants with enhanced integrity for soft tissue repair and regeneration
US6721142B1 (en) * 2000-12-21 2004-04-13 Western Digital (Fremont) Inc. Non-corrosive GMR slider for proximity recording
CA2365376C (en) 2000-12-21 2006-03-28 Ethicon, Inc. Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration
US20020114795A1 (en) * 2000-12-22 2002-08-22 Thorne Kevin J. Composition and process for bone growth and repair
AU2002247044B2 (en) * 2001-01-30 2006-11-16 Orthogene, Inc. Compositions and methods for the treatment and repair of defects or lesions in articular cartilage using synovial-derived tissue or cells
AUPR289601A0 (en) * 2001-02-05 2001-03-01 Commonwealth Scientific And Industrial Research Organisation Method of tissue repair
CA2438047A1 (en) * 2001-02-14 2002-08-22 Hildegard M. Kramer Biocompatible fleece for hemostasis and tissue engineering
US8062377B2 (en) 2001-03-05 2011-11-22 Hudson Surgical Design, Inc. Methods and apparatus for knee arthroplasty
CA2681952A1 (en) * 2001-04-25 2002-10-31 Eidgenoessische Technische Hochschule Zurich Drug delivery matrices to enhance wound healing
US6713085B2 (en) 2001-04-27 2004-03-30 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method and membrane for mucosa regeneration
WO2002089711A1 (en) * 2001-05-07 2002-11-14 Crosscart, Inc. Submucosal xenografts
US8439926B2 (en) 2001-05-25 2013-05-14 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools
ATE504264T1 (de) 2001-05-25 2011-04-15 Conformis Inc Verfahren und zusammensetzungen zur reparatur der oberfläche von gelenken
US7476257B2 (en) * 2001-09-15 2009-01-13 Rush University Medical Center Methods to engineer stratified cartilage tissue
US20030165473A1 (en) * 2001-11-09 2003-09-04 Rush-Presbyterian-St. Luke's Medical Center Engineered intervertebral disc tissue
US6780841B2 (en) 2001-11-13 2004-08-24 Biocell Technology, Llc Hyaluronic acid and chondroitin sulfate based hydrolyzed collagen type II and method of making same
US7160725B2 (en) * 2001-11-13 2007-01-09 Curis, Inc. Hedgehog signaling promotes the formation of three dimensional cartilage matrices
CA2412012C (en) * 2001-11-20 2011-08-02 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage
US7232802B2 (en) 2001-12-21 2007-06-19 Zimmer Orthobiologics, Inc. Compositions and methods for promoting myocardial and peripheral angiogenesis
EP1466623B1 (en) * 2001-12-28 2009-04-22 Kyowa Hakko Kogyo Co., Ltd. Anti-fgf-8 antibodies against arthritis
US20030138873A1 (en) * 2002-01-22 2003-07-24 Koichi Masuda Tissue engineered cartilage for drug discovery
JP2005516972A (ja) * 2002-01-22 2005-06-09 ファイザー・インク 血栓疾患の治療のためのtafi−a阻害剤として使用される3−(イミダゾリル)−2−アミノプロピオン酸
CA2474645C (en) * 2002-02-01 2011-08-09 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US20050171616A1 (en) * 2002-02-04 2005-08-04 Hsing-Wen Sung Peritoneal regeneration with acellular pericardial patch
US20060014284A1 (en) * 2002-03-21 2006-01-19 Thomas Graeve Biomatrix and method for producting the same
AU2003226201A1 (en) * 2002-04-02 2003-10-20 William Marsh Rice University Redifferentiated cells for repairing cartilage defects
US20030205538A1 (en) 2002-05-03 2003-11-06 Randel Dorian Methods and apparatus for isolating platelets from blood
US7992725B2 (en) 2002-05-03 2011-08-09 Biomet Biologics, Llc Buoy suspension fractionation system
US7374678B2 (en) * 2002-05-24 2008-05-20 Biomet Biologics, Inc. Apparatus and method for separating and concentrating fluids containing multiple components
US7832566B2 (en) 2002-05-24 2010-11-16 Biomet Biologics, Llc Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles
WO2003099412A1 (en) 2002-05-24 2003-12-04 Biomet Manufacturing Corp. Apparatus and method for separating and concentrating fluids containing multiple components
US20060278588A1 (en) 2002-05-24 2006-12-14 Woodell-May Jennifer E Apparatus and method for separating and concentrating fluids containing multiple components
US7845499B2 (en) 2002-05-24 2010-12-07 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US7622562B2 (en) * 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
US20050130879A1 (en) * 2002-07-02 2005-06-16 Julia Hwang Modifying tissue surfaces by liquid crystal formation
CA2498212C (en) * 2002-09-10 2012-07-17 American National Red Cross Multi-layered hemostatic dressing comprising thrombin and fibrinogen
US20040136968A1 (en) * 2002-09-27 2004-07-15 Verigen Ag Autologous cells on a support matrix for tissue repair
TWI231755B (en) * 2002-10-07 2005-05-01 Conformis Inc An interpositional articular implant and the method for making the same
US20040078090A1 (en) * 2002-10-18 2004-04-22 Francois Binette Biocompatible scaffolds with tissue fragments
US7824701B2 (en) * 2002-10-18 2010-11-02 Ethicon, Inc. Biocompatible scaffold for ligament or tendon repair
WO2004039248A2 (en) * 2002-10-31 2004-05-13 The General Hospital Corporation Repairing or replacing tissues or organs
CN1780594A (zh) 2002-11-07 2006-05-31 康复米斯公司 用于确定半月板的大小和形状以及设计治疗的方法
US20050118236A1 (en) * 2002-12-03 2005-06-02 Gentis Inc. Bioactive, resorbable scaffolds for tissue engineering
EP1592373B1 (en) 2003-01-30 2013-04-24 ProChon Biotech Ltd. Freeze-dried fibrin matrices and methods for preparation thereof
EP1613364B1 (de) * 2003-02-26 2013-01-16 Zimmer Orthobiologics, Inc. Präparat zur reparatur von knorpelgewebe, insbesondere von gelenkknorpel-defekten
US8197837B2 (en) 2003-03-07 2012-06-12 Depuy Mitek, Inc. Method of preparation of bioabsorbable porous reinforced tissue implants and implants thereof
US7794408B2 (en) * 2003-03-28 2010-09-14 Ethicon, Inc. Tissue collection device and methods
US7067123B2 (en) 2003-04-29 2006-06-27 Musculoskeletal Transplant Foundation Glue for cartilage repair
US7901457B2 (en) 2003-05-16 2011-03-08 Musculoskeletal Transplant Foundation Cartilage allograft plug
US7488348B2 (en) * 2003-05-16 2009-02-10 Musculoskeletal Transplant Foundation Cartilage allograft plug
US8226715B2 (en) 2003-06-30 2012-07-24 Depuy Mitek, Inc. Scaffold for connective tissue repair
US10583220B2 (en) * 2003-08-11 2020-03-10 DePuy Synthes Products, Inc. Method and apparatus for resurfacing an articular surface
US8034003B2 (en) 2003-09-11 2011-10-11 Depuy Mitek, Inc. Tissue extraction and collection device
US7611473B2 (en) * 2003-09-11 2009-11-03 Ethicon, Inc. Tissue extraction and maceration device
WO2005035012A1 (en) * 2003-10-10 2005-04-21 Coloplast A/S A dressing
DE602004018534D1 (de) * 2003-10-10 2009-01-29 Kw2 Implantattechnologie Gmbh Knorpelregeneration mit generation von chondronen unter hoher konzentration von magnesium
US7316822B2 (en) * 2003-11-26 2008-01-08 Ethicon, Inc. Conformable tissue repair implant capable of injection delivery
US7901461B2 (en) 2003-12-05 2011-03-08 Ethicon, Inc. Viable tissue repair implants and methods of use
WO2005058207A1 (en) * 2003-12-11 2005-06-30 Isto Technologies, Inc. Particulate cartilage system
CA2535169A1 (en) 2003-12-31 2005-07-21 Osteotech, Inc. Improved bone matrix compositions and methods
US9814539B2 (en) * 2004-01-14 2017-11-14 Puget Bioventures Llc Methods and apparatus for conformable prosthetic implants
US7857814B2 (en) * 2004-01-14 2010-12-28 Hudson Surgical Design, Inc. Methods and apparatus for minimally invasive arthroplasty
US8114083B2 (en) 2004-01-14 2012-02-14 Hudson Surgical Design, Inc. Methods and apparatus for improved drilling and milling tools for resection
US20060030854A1 (en) 2004-02-02 2006-02-09 Haines Timothy G Methods and apparatus for wireplasty bone resection
US7815645B2 (en) * 2004-01-14 2010-10-19 Hudson Surgical Design, Inc. Methods and apparatus for pinplasty bone resection
US8021368B2 (en) 2004-01-14 2011-09-20 Hudson Surgical Design, Inc. Methods and apparatus for improved cutting tools for resection
CA2558661C (en) * 2004-02-06 2012-09-04 Georgia Tech Research Corporation Load bearing biocompatible device
WO2005077013A2 (en) 2004-02-06 2005-08-25 Georgia Tech Research Corporation Surface directed cellular attachment
US11395865B2 (en) * 2004-02-09 2022-07-26 DePuy Synthes Products, Inc. Scaffolds with viable tissue
US8221780B2 (en) * 2004-04-20 2012-07-17 Depuy Mitek, Inc. Nonwoven tissue scaffold
US8657881B2 (en) * 2004-04-20 2014-02-25 Depuy Mitek, Llc Meniscal repair scaffold
US8137686B2 (en) 2004-04-20 2012-03-20 Depuy Mitek, Inc. Nonwoven tissue scaffold
DE102004024635A1 (de) * 2004-05-12 2005-12-08 Deutsche Gelatine-Fabriken Stoess Ag Verfahren zur Herstellung von Formkörpern auf Basis von vernetzter Gelatine
US20050288796A1 (en) * 2004-06-23 2005-12-29 Hani Awad Native soft tissue matrix for therapeutic applications
US8512730B2 (en) 2004-07-12 2013-08-20 Isto Technologies, Inc. Methods of tissue repair and compositions therefor
US7335508B2 (en) * 2004-07-22 2008-02-26 Prochon Biotech Ltd. Porous plasma protein matrices and methods for preparation thereof
US7351423B2 (en) 2004-09-01 2008-04-01 Depuy Spine, Inc. Musculo-skeletal implant having a bioactive gradient
US7273756B2 (en) * 2004-10-01 2007-09-25 Isto Technologies, Inc. Method for chondrocyte expansion with phenotype retention
US7837740B2 (en) * 2007-01-24 2010-11-23 Musculoskeletal Transplant Foundation Two piece cancellous construct for cartilage repair
US20060111778A1 (en) * 2004-10-29 2006-05-25 Michalow Alexander E Methods of promoting healing of cartilage defects and method of causing stem cells to differentiate by the articular chondrocyte pathway
US7866485B2 (en) 2005-02-07 2011-01-11 Hanuman, Llc Apparatus and method for preparing platelet rich plasma and concentrates thereof
WO2006086201A2 (en) 2005-02-07 2006-08-17 Hanuman Llc Platelet rich plasma concentrate apparatus and method
WO2006086199A1 (en) * 2005-02-07 2006-08-17 Hanuman Llc Platelet rich plasma concentrate apparatus and method
US7815926B2 (en) 2005-07-11 2010-10-19 Musculoskeletal Transplant Foundation Implant for articular cartilage repair
EP1916964A4 (en) 2005-08-26 2015-11-04 Zimmer Inc IMPLANTS AND METHODS FOR THE REPAIR, REPLACEMENT AND TREATMENT OF JOINT DISEASES
ES2439943T3 (es) * 2005-09-02 2014-01-27 ED. Geistlich Söhne AG für Chemische Industrie Método de reparación de desgarros de menisco
WO2007035778A2 (en) 2005-09-19 2007-03-29 Histogenics Corporation Cell-support matrix and a method for preparation thereof
EP1764117A1 (en) 2005-09-20 2007-03-21 Zimmer GmbH Implant for the repair of a cartilage defect and method for manufacturing the implant
KR100720052B1 (ko) 2005-10-07 2007-05-18 (주) 차바이오텍 성장인자를 함유한 나노입자가 코팅된 연골 조직 재건 및재생을 위한 마이크로스피어 또는 마이크로비드
US20070135706A1 (en) * 2005-12-13 2007-06-14 Shimko Daniel A Debridement method, device and kit
US20090306776A1 (en) 2006-01-25 2009-12-10 Children's Medical Center Corporation Methods and procedures for ligament repair
US8623026B2 (en) 2006-02-06 2014-01-07 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools incorporating anatomical relief
US8500740B2 (en) 2006-02-06 2013-08-06 Conformis, Inc. Patient-specific joint arthroplasty devices for ligament repair
AU2007212033B2 (en) 2006-02-06 2014-01-23 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools
US10278711B2 (en) 2006-02-27 2019-05-07 Biomet Manufacturing, Llc Patient-specific femoral guide
US8298237B2 (en) 2006-06-09 2012-10-30 Biomet Manufacturing Corp. Patient-specific alignment guide for multiple incisions
US8535387B2 (en) 2006-02-27 2013-09-17 Biomet Manufacturing, Llc Patient-specific tools and implants
US9345548B2 (en) 2006-02-27 2016-05-24 Biomet Manufacturing, Llc Patient-specific pre-operative planning
US8858561B2 (en) 2006-06-09 2014-10-14 Blomet Manufacturing, LLC Patient-specific alignment guide
US8070752B2 (en) 2006-02-27 2011-12-06 Biomet Manufacturing Corp. Patient specific alignment guide and inter-operative adjustment
US8133234B2 (en) 2006-02-27 2012-03-13 Biomet Manufacturing Corp. Patient specific acetabular guide and method
US8591516B2 (en) 2006-02-27 2013-11-26 Biomet Manufacturing, Llc Patient-specific orthopedic instruments
US9173661B2 (en) 2006-02-27 2015-11-03 Biomet Manufacturing, Llc Patient specific alignment guide with cutting surface and laser indicator
US20150335438A1 (en) 2006-02-27 2015-11-26 Biomet Manufacturing, Llc. Patient-specific augments
US8568487B2 (en) 2006-02-27 2013-10-29 Biomet Manufacturing, Llc Patient-specific hip joint devices
US7967868B2 (en) 2007-04-17 2011-06-28 Biomet Manufacturing Corp. Patient-modified implant and associated method
US9289253B2 (en) 2006-02-27 2016-03-22 Biomet Manufacturing, Llc Patient-specific shoulder guide
US9339278B2 (en) 2006-02-27 2016-05-17 Biomet Manufacturing, Llc Patient-specific acetabular guides and associated instruments
US8241293B2 (en) 2006-02-27 2012-08-14 Biomet Manufacturing Corp. Patient specific high tibia osteotomy
US8473305B2 (en) 2007-04-17 2013-06-25 Biomet Manufacturing Corp. Method and apparatus for manufacturing an implant
US8608749B2 (en) 2006-02-27 2013-12-17 Biomet Manufacturing, Llc Patient-specific acetabular guides and associated instruments
US8603180B2 (en) 2006-02-27 2013-12-10 Biomet Manufacturing, Llc Patient-specific acetabular alignment guides
US8864769B2 (en) 2006-02-27 2014-10-21 Biomet Manufacturing, Llc Alignment guides with patient-specific anchoring elements
US8608748B2 (en) 2006-02-27 2013-12-17 Biomet Manufacturing, Llc Patient specific guides
US9907659B2 (en) 2007-04-17 2018-03-06 Biomet Manufacturing, Llc Method and apparatus for manufacturing an implant
US8092465B2 (en) 2006-06-09 2012-01-10 Biomet Manufacturing Corp. Patient specific knee alignment guide and associated method
US8407067B2 (en) 2007-04-17 2013-03-26 Biomet Manufacturing Corp. Method and apparatus for manufacturing an implant
US9918740B2 (en) 2006-02-27 2018-03-20 Biomet Manufacturing, Llc Backup surgical instrument system and method
US8377066B2 (en) 2006-02-27 2013-02-19 Biomet Manufacturing Corp. Patient-specific elbow guides and associated methods
US9113971B2 (en) 2006-02-27 2015-08-25 Biomet Manufacturing, Llc Femoral acetabular impingement guide
US8282646B2 (en) 2006-02-27 2012-10-09 Biomet Manufacturing Corp. Patient specific knee alignment guide and associated method
US8567609B2 (en) 2006-05-25 2013-10-29 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
US8430813B2 (en) * 2006-05-26 2013-04-30 Depuy Spine, Inc. Illuminated surgical access system including a surgical access device and integrated light emitter
US9795399B2 (en) 2006-06-09 2017-10-24 Biomet Manufacturing, Llc Patient-specific knee alignment guide and associated method
PL2056756T3 (pl) * 2006-08-04 2014-05-30 Stb Ltd Stały opatrunek do leczenia zranionej tkanki
EP2061429A2 (en) * 2006-09-07 2009-05-27 Ed. Geistlich Söhne Ag Für Chemische Industrie Method of treating bone cancer
CA2664866C (en) 2006-09-28 2018-08-14 Children's Medical Center Coporation Methods and collagen products for tissue repair
US8163549B2 (en) 2006-12-20 2012-04-24 Zimmer Orthobiologics, Inc. Method of obtaining viable small tissue particles and use for tissue repair
US7718616B2 (en) 2006-12-21 2010-05-18 Zimmer Orthobiologics, Inc. Bone growth particles and osteoinductive composition thereof
US8435551B2 (en) 2007-03-06 2013-05-07 Musculoskeletal Transplant Foundation Cancellous construct with support ring for repair of osteochondral defects
JP5479319B2 (ja) 2007-04-12 2014-04-23 バイオメット・バイオロジックス・リミテッド・ライアビリティ・カンパニー ブイ式懸濁液分画システム
US8328024B2 (en) 2007-04-12 2012-12-11 Hanuman, Llc Buoy suspension fractionation system
AU2008240191B2 (en) 2007-04-12 2013-09-19 Zimmer, Inc. Compositions and methods for tissue repair
ES2573327T3 (es) * 2007-04-23 2016-06-07 Baxter International Inc. Composiciones de fibrina que contienen compuestos de estroncio
US20080269762A1 (en) * 2007-04-25 2008-10-30 Biomet Manufacturing Corp. Method and device for repair of cartilage defects
WO2008157412A2 (en) 2007-06-13 2008-12-24 Conformis, Inc. Surgical cutting guide
ES2327480B1 (es) * 2007-06-15 2010-08-10 Bioiberica, S.A. "disacaridos para el tratamiento de tendones, ligamentos y huesos".
WO2009020612A1 (en) * 2007-08-06 2009-02-12 Stb Lifesaving Technologies, Inc. Methods and dressing for sealing internal injuries
US8062655B2 (en) * 2007-08-31 2011-11-22 Phillips Plastics Corporation Composite scaffold structure
US8265949B2 (en) 2007-09-27 2012-09-11 Depuy Products, Inc. Customized patient surgical plan
US8361076B2 (en) 2007-09-30 2013-01-29 Depuy Products, Inc. Patient-customizable device and system for performing an orthopaedic surgical procedure
US8357111B2 (en) 2007-09-30 2013-01-22 Depuy Products, Inc. Method and system for designing patient-specific orthopaedic surgical instruments
CA2710798A1 (en) * 2007-12-28 2009-07-09 Kuros Biosurgery Ag Pdgf fusion proteins incorporated into fibrin foams
US20090181807A1 (en) * 2008-01-16 2009-07-16 Jason Miguel De Los Santos Golfing aid
EP2620139B1 (en) 2008-02-27 2016-07-20 Biomet Biologics, LLC Interleukin-1 receptor antagonist rich solutions
US8337711B2 (en) 2008-02-29 2012-12-25 Biomet Biologics, Llc System and process for separating a material
US8682052B2 (en) 2008-03-05 2014-03-25 Conformis, Inc. Implants for altering wear patterns of articular surfaces
WO2009111069A1 (en) * 2008-03-05 2009-09-11 Musculoskeletal Transplant Foundation Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles
NZ623706A (en) 2008-05-05 2015-12-24 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
EP2303193A4 (en) 2008-05-12 2012-03-21 Conformis Inc DEVICES AND METHOD FOR TREATING CRANE AND OTHER JOINTS
US8012077B2 (en) * 2008-05-23 2011-09-06 Biomet Biologics, Llc Blood separating device
US9095551B2 (en) 2009-01-29 2015-08-04 Riken Combined preparation for treating joint diseases
US8170641B2 (en) 2009-02-20 2012-05-01 Biomet Manufacturing Corp. Method of imaging an extremity of a patient
US8808297B2 (en) 2009-02-24 2014-08-19 Microport Orthopedics Holdings Inc. Orthopedic surgical guide
US8808303B2 (en) 2009-02-24 2014-08-19 Microport Orthopedics Holdings Inc. Orthopedic surgical guide
US9017334B2 (en) 2009-02-24 2015-04-28 Microport Orthopedics Holdings Inc. Patient specific surgical guide locator and mount
US8187475B2 (en) 2009-03-06 2012-05-29 Biomet Biologics, Llc Method and apparatus for producing autologous thrombin
US8313954B2 (en) 2009-04-03 2012-11-20 Biomet Biologics, Llc All-in-one means of separating blood components
SG175276A1 (en) 2009-05-05 2011-11-28 Novimmune Sa Anti-il-17f antibodies and methods of use thereof
US9011800B2 (en) 2009-07-16 2015-04-21 Biomet Biologics, Llc Method and apparatus for separating biological materials
DE102009028503B4 (de) 2009-08-13 2013-11-14 Biomet Manufacturing Corp. Resektionsschablone zur Resektion von Knochen, Verfahren zur Herstellung einer solchen Resektionsschablone und Operationsset zur Durchführung von Kniegelenk-Operationen
JP4995888B2 (ja) * 2009-12-15 2012-08-08 株式会社神戸製鋼所 ステンレス鋼アーク溶接フラックス入りワイヤ
US8632547B2 (en) 2010-02-26 2014-01-21 Biomet Sports Medicine, Llc Patient-specific osteotomy devices and methods
US9066727B2 (en) 2010-03-04 2015-06-30 Materialise Nv Patient-specific computed tomography guides
US8591391B2 (en) 2010-04-12 2013-11-26 Biomet Biologics, Llc Method and apparatus for separating a material
US9271744B2 (en) 2010-09-29 2016-03-01 Biomet Manufacturing, Llc Patient-specific guide for partial acetabular socket replacement
AU2011329054B2 (en) 2010-11-15 2015-05-28 Zimmer Orthobiologics, Inc. Bone void fillers
US9968376B2 (en) 2010-11-29 2018-05-15 Biomet Manufacturing, Llc Patient-specific orthopedic instruments
WO2012112698A2 (en) 2011-02-15 2012-08-23 Conformis, Inc. Patient-adapted and improved articular implants, procedures and tools to address, assess, correct, modify and/or accommodate anatomical variation and/or asymmetry
US9241745B2 (en) 2011-03-07 2016-01-26 Biomet Manufacturing, Llc Patient-specific femoral version guide
US8715289B2 (en) 2011-04-15 2014-05-06 Biomet Manufacturing, Llc Patient-specific numerically controlled instrument
US9675400B2 (en) 2011-04-19 2017-06-13 Biomet Manufacturing, Llc Patient-specific fracture fixation instrumentation and method
US8956364B2 (en) 2011-04-29 2015-02-17 Biomet Manufacturing, Llc Patient-specific partial knee guides and other instruments
US8668700B2 (en) 2011-04-29 2014-03-11 Biomet Manufacturing, Llc Patient-specific convertible guides
CA3048437C (en) 2011-05-26 2022-06-21 Cartiva, Inc. Tapered joint implant and related tools
US8532807B2 (en) 2011-06-06 2013-09-10 Biomet Manufacturing, Llc Pre-operative planning and manufacturing method for orthopedic procedure
US9084618B2 (en) 2011-06-13 2015-07-21 Biomet Manufacturing, Llc Drill guides for confirming alignment of patient-specific alignment guides
WO2012173890A2 (en) 2011-06-16 2012-12-20 Smith & Nephew, Inc. Surgical alignment using references
US20130001121A1 (en) 2011-07-01 2013-01-03 Biomet Manufacturing Corp. Backup kit for a patient-specific arthroplasty kit assembly
US8764760B2 (en) 2011-07-01 2014-07-01 Biomet Manufacturing, Llc Patient-specific bone-cutting guidance instruments and methods
US8597365B2 (en) 2011-08-04 2013-12-03 Biomet Manufacturing, Llc Patient-specific pelvic implants for acetabular reconstruction
US9066734B2 (en) 2011-08-31 2015-06-30 Biomet Manufacturing, Llc Patient-specific sacroiliac guides and associated methods
US9295497B2 (en) 2011-08-31 2016-03-29 Biomet Manufacturing, Llc Patient-specific sacroiliac and pedicle guides
US9386993B2 (en) 2011-09-29 2016-07-12 Biomet Manufacturing, Llc Patient-specific femoroacetabular impingement instruments and methods
US9554910B2 (en) 2011-10-27 2017-01-31 Biomet Manufacturing, Llc Patient-specific glenoid guide and implants
US9451973B2 (en) 2011-10-27 2016-09-27 Biomet Manufacturing, Llc Patient specific glenoid guide
US9301812B2 (en) 2011-10-27 2016-04-05 Biomet Manufacturing, Llc Methods for patient-specific shoulder arthroplasty
KR20130046337A (ko) 2011-10-27 2013-05-07 삼성전자주식회사 멀티뷰 디바이스 및 그 제어방법과, 디스플레이장치 및 그 제어방법과, 디스플레이 시스템
EP2770918B1 (en) 2011-10-27 2017-07-19 Biomet Manufacturing, LLC Patient-specific glenoid guides
WO2013116744A1 (en) 2012-02-01 2013-08-08 Children's Medical Center Corporation Biomaterial for articular cartilage maintenance and treatment of arthritis
US9237950B2 (en) 2012-02-02 2016-01-19 Biomet Manufacturing, Llc Implant with patient-specific porous structure
US9486226B2 (en) 2012-04-18 2016-11-08 Conformis, Inc. Tibial guides, tools, and techniques for resecting the tibial plateau
US9675471B2 (en) 2012-06-11 2017-06-13 Conformis, Inc. Devices, techniques and methods for assessing joint spacing, balancing soft tissues and obtaining desired kinematics for joint implant components
US9642956B2 (en) 2012-08-27 2017-05-09 Biomet Biologics, Llc Apparatus and method for separating and concentrating fluids containing multiple components
AU2013342255B2 (en) 2012-11-08 2017-05-04 Smith & Nephew, Inc. Methods and compositions suitable for improved reattachment of detached cartilage to subchondral bone
WO2014074806A1 (en) 2012-11-08 2014-05-15 Smith & Nephew, Inc-- Improved reattachment of detached cartilage to subchondral bone
US10245306B2 (en) 2012-11-16 2019-04-02 Isto Technologies Ii, Llc Flexible tissue matrix and methods for joint repair
US9204977B2 (en) 2012-12-11 2015-12-08 Biomet Manufacturing, Llc Patient-specific acetabular guide for anterior approach
US9060788B2 (en) 2012-12-11 2015-06-23 Biomet Manufacturing, Llc Patient-specific acetabular guide for anterior approach
US20140178343A1 (en) 2012-12-21 2014-06-26 Jian Q. Yao Supports and methods for promoting integration of cartilage tissue explants
EP2951193A4 (en) 2013-02-01 2017-03-01 Children's Medical Center Corporation Collagen scaffolds
US9839438B2 (en) 2013-03-11 2017-12-12 Biomet Manufacturing, Llc Patient-specific glenoid guide with a reusable guide holder
US9579107B2 (en) 2013-03-12 2017-02-28 Biomet Manufacturing, Llc Multi-point fit for patient specific guide
US9498233B2 (en) 2013-03-13 2016-11-22 Biomet Manufacturing, Llc. Universal acetabular guide and associated hardware
US9826981B2 (en) 2013-03-13 2017-11-28 Biomet Manufacturing, Llc Tangential fit of patient-specific guides
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US9517145B2 (en) 2013-03-15 2016-12-13 Biomet Manufacturing, Llc Guide alignment system and method
US20150112349A1 (en) 2013-10-21 2015-04-23 Biomet Manufacturing, Llc Ligament Guide Registration
US10282488B2 (en) 2014-04-25 2019-05-07 Biomet Manufacturing, Llc HTO guide with optional guided ACL/PCL tunnels
US9408616B2 (en) 2014-05-12 2016-08-09 Biomet Manufacturing, Llc Humeral cut guide
US9561040B2 (en) 2014-06-03 2017-02-07 Biomet Manufacturing, Llc Patient-specific glenoid depth control
US9839436B2 (en) 2014-06-03 2017-12-12 Biomet Manufacturing, Llc Patient-specific glenoid depth control
EP3167049A4 (en) * 2014-07-08 2017-11-29 MIMEDX Group Inc. Micronized wharton's jelly
US9826994B2 (en) 2014-09-29 2017-11-28 Biomet Manufacturing, Llc Adjustable glenoid pin insertion guide
US9833245B2 (en) 2014-09-29 2017-12-05 Biomet Sports Medicine, Llc Tibial tubercule osteotomy
US10179191B2 (en) 2014-10-09 2019-01-15 Isto Technologies Ii, Llc Flexible tissue matrix and methods for joint repair
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
US9713810B2 (en) 2015-03-30 2017-07-25 Biomet Biologics, Llc Cell washing plunger using centrifugal force
US9820868B2 (en) 2015-03-30 2017-11-21 Biomet Manufacturing, Llc Method and apparatus for a pin apparatus
EP3636226A1 (en) 2015-03-31 2020-04-15 Cartiva, Inc. Carpometacarpal (cmc) implants
WO2016161025A1 (en) 2015-03-31 2016-10-06 Cartiva, Inc. Hydrogel implants with porous materials and methods
WO2016168363A1 (en) 2015-04-14 2016-10-20 Cartiva, Inc. Tooling for creating tapered opening in tissue and related methods
US9757721B2 (en) 2015-05-11 2017-09-12 Biomet Biologics, Llc Cell washing plunger using centrifugal force
US10226262B2 (en) 2015-06-25 2019-03-12 Biomet Manufacturing, Llc Patient-specific humeral guide designs
US10568647B2 (en) 2015-06-25 2020-02-25 Biomet Manufacturing, Llc Patient-specific humeral guide designs
WO2017023657A1 (en) 2015-07-31 2017-02-09 The Procter & Gamble Company Forming belt for shaped nonwoven
BR112018002059B1 (pt) 2015-07-31 2023-02-14 The Procter & Gamble Company Embalagem de artigos para cuidados pessoais
SI3239378T1 (sl) 2016-04-29 2019-06-28 Reifenhaeuser Gmbh & Co. Kg Maschinenfabrik Naprava in postopek za izdelavo kopren iz brezkončnih filamentov
US10722310B2 (en) 2017-03-13 2020-07-28 Zimmer Biomet CMF and Thoracic, LLC Virtual surgery planning system and method
KR102245539B1 (ko) 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
US11051829B2 (en) 2018-06-26 2021-07-06 DePuy Synthes Products, Inc. Customized patient-specific orthopaedic surgical instrument
CA3117214C (en) 2018-11-01 2022-08-30 Oil States Energy Services, L.L.C. Valve with pressure differential seating
US20230256138A1 (en) * 2020-05-14 2023-08-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Composite product for the osteoarticular regeneration of cartilage lesion
CN114984298A (zh) * 2022-07-18 2022-09-02 重庆大学 一类软骨组织粘合剂及其制备方法和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986000526A1 (en) * 1984-07-05 1986-01-30 Caplan Arnold I Process for adapting soluble bone protein for use in stimulating osteoinduction
EP0361896A2 (en) * 1988-09-29 1990-04-04 Collagen Corporation Method for improving implant fixation
WO1990009783A1 (en) * 1989-02-22 1990-09-07 Massachusetts Institute Of Technology Delivery system for controlled release of bioactive factors

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966908A (en) * 1973-11-29 1976-06-29 Lescarden Ltd. Method of treating degenerative joint afflictions
US4761471A (en) * 1980-08-04 1988-08-02 The Regents Of The University Of California Bone morphogenetic protein composition
US4346709A (en) * 1980-11-10 1982-08-31 Alza Corporation Drug delivery devices comprising erodible polymer and erosion rate modifier
US4418691A (en) * 1981-10-26 1983-12-06 Massachusetts Institute Of Technology Method of promoting the regeneration of tissue at a wound
US4440750A (en) * 1982-02-12 1984-04-03 Collagen Corporation Osteogenic composition and method
IL68218A (en) * 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
CA1230591A (en) * 1983-06-03 1987-12-22 Charles A. Frolik PURIFIED TRANSFORMING GROWTH FACTOR-.beta. DERIVED FROM HUMAN PLATELETS AND PLACENTAS
JPS6028999A (ja) * 1983-06-30 1985-02-14 Maruho Kk 細胞増殖促進作用を有するたんぱく質、その組成物と製造方法
US4795804A (en) * 1983-08-16 1989-01-03 The Regents Of The University Of California Bone morphogenetic agents
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4804744A (en) * 1984-01-04 1989-02-14 International Genetic Engineering, Inc. Osteogenic factors
US4956455A (en) * 1984-03-05 1990-09-11 The Salk Institute For Biological Studies Bovine fibroblast growth factor
US4785079A (en) * 1984-11-09 1988-11-15 The Salk Institute For Biological Studies Isolation of fibroblast growth factor
US4609551A (en) * 1984-03-20 1986-09-02 Arnold Caplan Process of and material for stimulating growth of cartilage and bony tissue at anatomical sites
US4619913A (en) * 1984-05-29 1986-10-28 Matrix Pharmaceuticals, Inc. Treatments employing drug-containing matrices for introduction into cellular lesion areas
US4843063A (en) * 1984-07-16 1989-06-27 Collagen Corporation Polypeptide cartilage-inducing factors found in bone
DE3588058T3 (de) * 1984-07-16 2005-04-07 Celtrix Pharmaceuticals, Inc., Palo Alto Knorpel-induzierende Polypeptid-Faktoren aus Knochen
US4627982A (en) * 1984-07-16 1986-12-09 Collagen Corporation Partially purified bone-inducing factor
US4888366A (en) * 1984-10-24 1989-12-19 Collagen Corporation Inductive collagen-based bone repair preparations
US4563350A (en) * 1984-10-24 1986-01-07 Collagen Corporation Inductive collagen based bone repair preparations
US4638045A (en) * 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4886747A (en) * 1985-03-22 1989-12-12 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US4839215A (en) * 1986-06-09 1989-06-13 Ceramed Corporation Biocompatible particles and cloth-like article made therefrom
IL83003A (en) * 1986-07-01 1995-07-31 Genetics Inst Factors that soak bone formation
US4877864A (en) * 1987-03-26 1989-10-31 Genetics Institute, Inc. Osteoinductive factors
US4931548A (en) * 1987-01-30 1990-06-05 Techne Corporation Heterodimer form of transforming growth factor-beta
AU626524B2 (en) * 1987-05-29 1992-08-06 Bristol-Myers Squibb Company Cloning and expression of simian transforming growth factor- beta 1
US4846835A (en) * 1987-06-15 1989-07-11 Grande Daniel A Technique for healing lesions in cartilage
US4952404A (en) * 1987-06-19 1990-08-28 President And Fellows Of Harvard College Promotion of healing of meniscal tissue
US4952403A (en) * 1987-06-19 1990-08-28 President And Fellows Of Harvard College Implants for the promotion of healing of meniscal tissue
DE3727606A1 (de) * 1987-08-19 1989-05-03 Aesculap Ag Verfahren zur herstellung eines knochenersatzmaterials
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
US5221620A (en) * 1987-10-06 1993-06-22 Oncogen Cloning and expression of transforming growth factor β2
EP0386109A1 (en) * 1987-11-12 1990-09-12 Schering Corporation Acceleration of bone formation with gm-csf
CA1339083C (en) * 1987-11-13 1997-07-29 Steven R. Jefferies Bone repair material and delayed drug delivery system
US4863732A (en) * 1987-12-16 1989-09-05 Collagen Corporation Injectable composition for inductive bone repair
US5049659A (en) * 1988-02-09 1991-09-17 Dana Farber Cancer Institute Proteins which induce immunological effector cell activation and chemattraction
GB8803697D0 (en) * 1988-02-17 1988-03-16 Deltanine Research Ltd Clinical developments using amniotic membrane cells
AU628050B2 (en) * 1988-04-08 1992-09-10 Stryker Corporation Biosynthetic osteogenic proteins and osteogenic devices containing them
US4975526A (en) * 1989-02-23 1990-12-04 Creative Biomolecules, Inc. Bone collagen matrix for zenogenic implants
EP0418234B1 (en) * 1988-06-08 1994-03-23 Genentech, Inc. NUCLEIC ACID ENCODING TGF-$g(b)3 AND ITS USE
IL90683A0 (en) * 1988-06-27 1990-01-18 Yissum Res Dev Co Osteogenic growth factors derived from regenerating bone marrow
US4950483A (en) * 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
US5106626A (en) * 1988-10-11 1992-04-21 International Genetic Engineering, Inc. Osteogenic factors
IE61346B1 (en) * 1988-11-02 1994-11-02 Genentech Inc A permeable material to fit around the teeth or gums of a mammal
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
CA2005120A1 (en) * 1988-12-15 1990-06-15 Anthony F. Purchio Tgf-beta 1/beta 2: a novel chimeric transforming growth factor-beta
WO1990006767A1 (en) * 1988-12-20 1990-06-28 La Jolla Cancer Research Foundation Polypeptide-polymer conjugates active in wound healing
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
EP0384731B1 (en) * 1989-02-23 1996-12-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Osteogenic growth polypeptides identified from regenerating bone marrow
CA2027583A1 (en) * 1989-02-23 1990-08-24 Victor P. Terranova Periodontal and bone regeneration factor, materials and methods
US4944948A (en) * 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
CA2016235C (en) * 1989-05-09 2002-03-12 Alan J. Fischman Labeled chemotactic peptides to image focal sites of infection or inflammation
ES2093647T3 (es) * 1989-06-05 1997-01-01 Massachusetts Inst Technology Polimeros bioerosionables para la liberacion de farmacos en los huesos.
US5158934A (en) * 1989-09-01 1992-10-27 Genentech, Inc. Method of inducing bone growth using TGF-β
US5043431A (en) * 1989-09-11 1991-08-27 Codon Method and apparatus for the production of TGF-β
US5206023A (en) * 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986000526A1 (en) * 1984-07-05 1986-01-30 Caplan Arnold I Process for adapting soluble bone protein for use in stimulating osteoinduction
EP0361896A2 (en) * 1988-09-29 1990-04-04 Collagen Corporation Method for improving implant fixation
WO1990009783A1 (en) * 1989-02-22 1990-09-07 Massachusetts Institute Of Technology Delivery system for controlled release of bioactive factors

Also Published As

Publication number Publication date
AU667032B2 (en) 1996-03-07
AU1412892A (en) 1992-09-07
DE69202332D1 (de) 1995-06-08
WO1992013565A1 (en) 1992-08-20
DK0569541T3 (da) 1995-07-10
NO307735B1 (no) 2000-05-22
HK1006416A1 (en) 1999-02-26
EP0569541A1 (en) 1993-11-18
NO932748L (no) 1993-09-29
ZA92726B (en) 1992-11-25
NZ260125A (en) 1997-07-27
US5368858A (en) 1994-11-29
CA2101556C (en) 2002-07-23
IE67515B1 (en) 1996-04-03
DE69202332T2 (de) 1996-01-04
IE920309A1 (en) 1992-07-29
CA2101556A1 (en) 1992-08-01
IL100799A (en) 1996-10-16
ES2072144T3 (es) 1995-07-01
KR100235391B1 (ko) 1999-12-15
EP0569541B1 (en) 1995-05-03
ATE121943T1 (de) 1995-05-15
NO932748D0 (no) 1993-07-30
IL100799A0 (en) 1992-09-06
JPH06505258A (ja) 1994-06-16
JP2004230184A (ja) 2004-08-19
TW214514B (zh) 1993-10-11
CN1064813A (zh) 1992-09-30
US5206023A (en) 1993-04-27

Similar Documents

Publication Publication Date Title
CN1056083C (zh) 治疗及修复软骨缺损或损伤的方法及组合物
CN1321681C (zh) 使用功能性屏障治疗和修复软骨或骨缺损或损伤的方法及组合物
AU657888B2 (en) Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
AU2008286357B2 (en) Repair of lesions in cartilage and bone using a chondro-regulative matrix
JP2004531534A (ja) 創傷治癒を促進する薬物送達マトリックス
JPH09500897A (ja) 銅と細胞接着タンパク質との錯体
EP1467748A1 (en) Stimulation of bone growth and cartilage formation with thrombing peptide derivatives
AU2002239965A1 (en) Stimulation of bone growth and cartilage formation with thrombing peptide derivatives
Tsuzuki et al. Effect of biodegradable gelatin β-tri calcium phosphate sponges containing mesenchymal stem cells and bone morphogenetic protein-2 on equine bone defect
CA2258601C (en) Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone using functional barrier
TW505518B (en) Compositions for the treatment and repair of defects or lesions in cartilage or bone using functional barrier

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C15 Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993)
OR01 Other related matters
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee